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Human immunodeficiency virus type 1 (HIV-1) emerged in the human population shortly after 
the turn of the 19th century. Distribution of HIV-1 across the globe over the past 30–35 years 
can be traced to founder events with primordial HIV strains from sub-Saharan Africa. Even 
considering the burden of HIV in Africa, our knowledge of HIV-1 disease is still largely limited 
to subtype B HIV-1, a strain responsible for 3 million infections in North America and Europe 
as compared to the 33 million that are infected with HIV-1 subtypes A, C, D, and circulating 
and unique recombinant forms.  
This dissertation analyzes data and archived samples from a cohort of HIV+ women in Uganda 
and Zimbabwe to assess the role of HIV-1 Group M subtype in disease progression, viral 
replicative fitness and cellular entry efficiency. Generalized estimating equation models are 
employed to calculate average rates of CD4+ T-cell loss over the course of disease, investigate 
circulating viral load, and compare depletion of memory T-cell subsets in CD4+ and CD8+ T-
cells. Fluorescent tissue culture assays of HIV-1 entry were used to phenotypically evaluate 
entry efficiency and its association with replicative fitness. 
Ugandan and Zimbabwean women infected with HIV-1 subtype C had 2.5-fold slower rates of 
CD4 T-cell declines and higher frequencies of long-term non-progression than those infected 
with subtype A or D, a difference not associated with any other clinical parameters. Relative 
replicative fitness and entry efficiency of HIV-1 variants directly correlated with virulence in 
the patients, subtype D > A > C. These relationships were maintained in both assays evaluating 
HIV-induced cell-fusion rates, viral particle entry rates and CD4 receptor affinity. 
The primary burden of HIV infection is placed on T-cell memory populations that are focal 
points for progeny virion production, the latent proviral reservoir, and immune activation. All 
subtypes depleted effector memory T-cells preferentially, however subtype D infections lost 
these cells at about twice the rate of subtype C infections. Finally, subtype D was found to  
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Chapter 1  
Introduction 
Approximately 35 million people have died from HIV/AIDS. Over 37 million more are 
currently infected [1]. The past, present and future of the entire African continent have 
been shaped by it. But for the first time, HIV appears beatable: new infections have slowed, 
global prevention initiatives funded and implemented, and science has made tremendous 
progress controlling and preventing infections. Whether the future holds a vaccine, 
sterilizing cure or additional international programs pushing to prevent transmissions, the 
tide has already turned. It’s only in the light of this potential that we can look back to learn 
from this disease, to inform future HIV policies, but also to prevent other zoonotic, or 
animal borne diseases in the future.  
1.1. The Cut Hunter Hypothesis 
A young man, starving and exhausted from overwork in the rubber tree plantations of the 
Belgian Congo, hunts in the jungle [2, 3]. It’s approximately 1931 (best estimates place it 
between 1915 and 1941) and food has become so scarce that he is forced to expand his 
typical dietary choices [4-7]. Bush meat, or the practice of hunting and eating jungle 
animals, has become a mainstay in his diet. Chimpanzees were a particularly common prey 
since they are large, relatively abundant, and accustomed to human interaction along the 
edges of the jungle [8-12]. In this account, the hunter is pursuing the local chimpanzee 
subspecies, the Central chimpanzee (Pan troglodytes troglodytes), armed with rudimentary 
equipment: dull knives or sharpened metal implements. Exhaustion provides enough of an 
impediment for the hunter to make a deadly mistake. While killing a chimpanzee the hunter 
injures himself, and the strain of the simian immunodeficiency virus (SIV) this chimpanzee 
harbors was able to reach his bloodstream. Unaware of the virus he is carrying, this man 
disregards the mild fever he gets over the next week. These symptoms resolve without 
long-term complications. Sometime within the next few years, this man leaves the rubber 
plantations and relocates by train to the local metropolitan center of Kinshasa, Zaire (now 
the Democratic Republic of the Congo or DRC) [10, 13]. The future will call him patient 
zero, the first human to begin spreading the human immunodeficiency virus (HIV). 
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Social, political and environmental changes in the Congo Basin during this period suggest 
that this account of the “Cut Hunter” hypothesis may oversimplify the drivers of zoonosis 
[10, 14]. Transmission of the virus very likely involved blood-blood contact, due to the far 
greater likelihood of successful infection, but butchering of primate meat is a much more 
likely cause of transmission, not an incident during hunting itself. Today bush meat hunting 
is still practiced and the butchering process is a source of many viral zoonoses [15-17]. The 
abrupt economic retraction stemming from the Great Depression in the 1920s, not colonial 
abuses, were the likely push to expand primate hunting, though not dramatically, which 
had been practiced to some extent for at least 3,000 years [18]. By the 1920s these hunts 
were likely safer than they had been in the past, as firearms were commonly used in 
protection, warfare, and hunting since the mid-19th century [19]. Belgian rule over Congo 
didn’t dramatically change firearm usage or ownership among rural African people, and 
most historians conclude that the slow expansion and accumulation of modern weaponry 
in Western and Central Africa remained steady through the late 19th and early 20th centuries 
[20]. Additionally, intentional food shortages and extreme cruelty to the native Congolese 
were curbed in 1908 after the transition from the Congo Free State, ostensibly privately 
managed by Kind Leopold II, to the Belgian Congo. The new leadership, while still 
oppressive, sought to improve the conditions of Congolese workers to curtail international 
criticism of slavery and abuse.  
These historical data, while sparse, suggest there is no force that accounts for a dramatic 
increase in SIV exposure in the early 20th century that had not existed previously. The 
changes in the Congo during this period were primarily in the movement of people, both 
through forced relocations to work in the metal mines in the South and voluntary relocation 
to major population centers [20]. Colonialism poured money into the resource-rich Congo 
to rapidly develop huge plantations to produce rubber, palm oil and cotton while the South 
was torn open for extensive copper mining. Thus, it is logical that humans have likely been 
infrequently exposed to SIV for millennia, but widespread dissemination of these diseases 
was limited. Forest societies in the region had always been mobile, but the construction of 
extensive railway networks in the 1910s-20s allowed for greater transportation. Quickly 
growing population centers like Kinshasa, a railroad hub that doubled in population 
between 1920-1940, became focal points for viral transmission. While it would be easy to 
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blame colonial cruelty as the root of the global HIV-1 pandemic, it’s likely that many 
shifting environmental and social disturbances under colonialism, rather than the human 
rights’ abuses, were the underlying drivers. 
1.2. Alternative Theories 
Occasionally, researchers and conspiracy theorists have offered alternative theories about 
the origins of HIV. Most pervasive among them is the theory put forward by Tom Curtis 
in Rolling Stone magazine in 1992; contaminated plasma from an SIV infected chimpanzee 
was used in developing the oral polio vaccine (OPV) in the Stanleyville region of the 
Belgian Congo [21]. The vaccine was deployed to approximately a million Africans 
between 1957-1960, an appealing theory to those who believe that a single infected 
individual couldn’t be the origin of the pandemic. By exposing such a large population to 
SIV, the theory states, it becomes much more likely to encounter an immunocompromised 
individual who could support viral replication, regardless of how maladapted this virus was 
to infecting humans. Despite the appeals of the contaminated polio vaccine theory, there is 
no evidence of accidental or negligent infection of African populations with SIV/HIV due 
to medical treatment. Employees at the facility in Stanleyville recall that chimpanzee 
tissues were never cultured due to safety concerns, and that the vaccines administered in 
the region were produced outside of Africa [22, 23]. These facts did little to dissuade those 
who believed this theory and pushed researchers to identify the source of HIV-1 infections 
in Africa. 
The final blow to the contaminated OPV theory came in 2010. Published in Nature, work 
from the groups of Drs. Beatrice Hahn and George Shaw conclusively demonstrated that, 
while the Eastern chimpanzees (Pan troglodytes schweinfurthii) of the Stanleyville region 
are endemically infected with SIV (SIVcpzPts), this strain does not resemble the SIVcpz 
strain that led to the Group M epidemic (SIVcpzPtt, Central Chimpanzee, Figure 1.1), or 
any transmissions establishing the HIV-1 or HIV-2 epidemics [24-28]. The geographic 
isolation of the chimpanzee subspecies that harbor these different SIVcpz strains, about 
800km between their ranges, makes it impossible for these subspecies to mix and there are 
no known incidents of SIVcpzPts strains infecting either humans or any other primate 
species [27, 28]. In later work, Hahn and Shaw demonstrated that the SIVcpzPts strain in 
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the Eastern chimpanzees of the Stanleyville region cluster as an outgroup to SIVcpzPtt, 
HIV-1 Group M and SIVgor [3]. This data conclusively identified SIVcpzPtt from Pan 
troglodytes troglodytes chimpanzees from the Kinshasa region as the origins of both HIV-
1 Group M and N, as well as infecting gorillas to establish SIVgor which in turn later 
transmitted to humans to found the Group O and P outbreaks. Finally, the timing of the 
deployment of the oral polio vaccine in the late 1950s is several decades too late to coincide 
with the origins of the Group M epidemic, situated around 1931 (95% confidence interval 
between 1915-1941) [3-7]. The story of the cut hunter, while flexible in details, provides 
the most realistic framework available to understand the origins of HIV group diversity. 
1.3. SIV Diversity and Pathogenesis 
Distinct SIV strains infect over 40 different primate species and subspecies ranging 
throughout Africa [29]. Most of these viruses are non-pathogenic in their hosts. For 
example, Gorillas and sooty mangabeys in Africa, infected with SIVgor and SIVsmm 
respectively, maintain high circulating viral loads but only rarely experience 
immunodeficiency symptoms, and in those cases these symptoms manifest only in the 
presence of exacerbating factors (e.g. advanced age or other infections) [30]. Loss of 
virulence due to evolutionary attenuation has been observed in many viruses, though this 
cannot be demonstrated experimentally in SIV [31-33]. Using genomic data from all SIV 
lineages and models accounting for both host specific and independent molecular clocks, 
the common ancestor of all SIVs is estimated to have existed between 2.5 and 5 million 
years ago [34-36]. This loosely coincides with the diversification of the primate species 
themselves, suggesting the virus and NHPs have coexisted through evolutionary time. It’s 
important to note that in cases of cross infection with SIVs from other primate species, the 
subsequent recombination has made estimates of SIV origin notoriously difficult and the 





Figure 1.1) SIV origins of HIV infections with relative pathogenicity between groups. 
Arrows denote transmission events between species, both between non-human primates 
and, in the rightmost arrows, into humans in Central and Western Africa. The average 
pathogenicity of each HIV variant can be ranked by the reported rates of CD4+ T-cell 
depletion that they cause, illustrated on the far right [38-60]. Approximate numbers of HIV 
infection denoted in parenthesis. Dashed lines denote groups with such small numbers of 




A small number of these SIVs can cause immunodeficiency when infecting a non-host 
primate species, particularly Sooty mangabey SIVs infecting the three Asian macaque 
species. The most common example of this is in the Asian primate Rhesus macaques, 
which, when infected by SIVmac239 (a misnomer as this strain originated in Sooty 
mangabeys) are the prototypic immunodeficiency model used by researchers globally [61-
63]. SIVmac239 infected macaques display many of the same markers of disease 
progression as human immunodeficiency including the loss of CD4+ T-cells, loss of CD8+ 
T-cell function, degenerative changes in lymph node architecture, and neurological 
symptoms. Much like HIV infections in humans, SIVmac infected macaques die from a 
range opportunistic diseases [61, 62].  
In the mid-1990s, researchers focused on identifying new SIV strains in reclusive monkey 
species. By sequencing these new SIV strains, key discoveries were made regarding global 
SIV diversity. Early phylogenies showed that each primate species’ SIV strain was 
monophyletic, evolving with their primate host. However, more complete sequences of the 
new SIV genomes showed that a few SIV strains thought to be evolutionarily distinct were 
closely related and shared a recent common ancestor [63-66]. The assembled phylogenies 
from these studies showed 5 groups of SIVs that displayed evidence of recent transmission 
events between NHP species [29, 67]. The rest of the 40 known SIV strains are species 
specific and it has been hypothesized that these viruses are adapted to their host species 
and are non-transmissible [68, 69]. For example, SIV in the Sykes’ monkeys 
(Cercopithecus albogularis) is phylogenetically unique and has never successfully 
transmitted from its host species, despite regular interactions in the wild with other SIV 
infected primates [70]. Monkeys that are preyed upon but do not hunt other primates 
themselves, like the African green monkeys (Chlorocebus spp.), also harbor unique SIV 
strains (SIVagm) that do not show evidence of recombination with other SIVs [65, 67]. 
SIVcpz, the ancestral source of the most pathogenic HIV-1 groups, M and N, diverges 
significantly from the timeline of other SIVs [70]. Dating of SIVcpz divergence suggests 
that chimpanzees acquired the virus long after diversifying from gorillas and bonobos, their 
next closest primate relatives [4, 6]. This is especially likely due to the lack of SIV strains 
infecting the Western and Nigerian/Cameroonian Chimpanzee subspecies, which diverged 
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from the Eastern and Central Chimpanzee species during the last 500,000 years [35, 36]. 
Observations by the eminent primatologist/anthropologist Jane Goodall suggest that 
hunting of other primate species by chimpanzees is the most likely source of SIV zoonotic 
transmission [71, 72]. SIVcpz, when aligned to other closely related SIV strains, resembles 
a mosaic of SIVs from Greater spot-nosed monkeys, Mustached monkeys, Mona monkeys 
and Red-capped mangabeys, all prey species for Eastern and Central Chimpanzees [65, 67, 
73] (Figure 1.1). Hunting as a mode of viral transmissions also agrees with the “missing” 
SIV in Nigerian/Cameroonian Chimpanzee subspecies since they exclusively prey on 
monkeys lacking SIV [74].  
If SIV attenuated over time to become less pathogenic, then this more recent acquisition of 
SIV correlates with the intermediate level of pathogenicity observed in naturally infected 
chimpanzees relative to other SIVs. When infected, these apes display high viral loads and 
some symptoms of immunodeficiency, including reduced numbers of circulating CD4+ T-
cells and structural changes in their lymph nodes [24]. One key difference, however, is the 
lack of AIDS-defining illnesses and opportunistic infection based-mortality in these 
monkeys. Lifespan is significantly reduced but typically due thrombocytopenia leading to 
heart failure, a comorbidity during SIV infection that is also occasionally observed in 
chronically infected HIV patients.  
1.4. HIV Diversity 
The most conservative estimates require at least twelve independent transmission events 
of SIV into human populations of Africa, and very likely many more. The earliest 
transmissions (1920-1930) led to the establishment of HIV-1 Groups M and N (from 
SIVcpzPtt) and HIV-1 Group O (from SIVgor) [75-77]. Other HIVs appear to have arisen 
from transmission events far more recently; HIV-2 (from SIVsmm in eight independent 
events) likely transmitted in the 1960s and HIV-1 Group P and the SIV strain infecting 
Western lowland gorillas (SIVgor) separating in approximately 1970 [6, 38, 78, 79] (Figure 
1.1). The eight HIV-2 transmissions are geographically isolated from the rest of the SIV 
transmissions, located much further northwest in Guinea-Bissau. A war for independence 
in the region lasted from 1963-1974 against the Portuguese, displacing large numbers to 
neighboring countries. It has been hypothesized that this abrupt displacement to larger 
8 
 
population centers, much like in the Belgian Congo in the 1920s and 1930s, provided the 
ideal environment for establishing a new HIV epidemic [6, 38, 79]. 
All forms of HIV lead to immunodeficiency, however they vary significantly in the rate at 
which the disease they cause progresses (Figure 1.1). HIV-2 has been shown to cause a 
very slowly progressing disease and has been typically geographically restricted to West 
Africa due to poor transmission efficiency [39-41]. Those infected with HIV-2 generally 
have very low viral loads, near the limit of detection, likely a major factor in the limited 
transmissibility of these viruses [42]. This is especially evident in mother-to-child 
transmissions, where ~30% of infants born to HIV-1-infected women become infected in 
the absence of preventive interventions, while only about 1% of HIV-2-infected mothers 
pass the virus to their infants [43-46]. Other studies in Western Africa have shown a 
reduction in the time to AIDS when patients are infected with HIV-1 and 2 simultaneously 
compared to HIV-1 alone [48]. The average time to the onset of AIDS in the absence of 
treatment is about 8 years in a patient infected with a HIV-1 Group M subtype B virus [49]. 
In stark contrast, the same patient infected with an HIV-2 virus would reach clinical AIDS 
in approximately 14-23 years [47]. 
Globally, HIV-2 makes up fewer than 5% of all HIV infections and has been declining 
over the last decade, in contrast to HIV-1 that has increased dramatically in prevalence 
over that same period. HIV-1 infections make up the remaining ~95% of global infections 
and are approximately 55-75% divergent from HIV-2 at the nucleotide level [38, 39]. Very 
small numbers of geographically isolated human infections by HIV-1 Groups N and P 
viruses have been observed, each genetically differing from each other group by ~45% [50-
54]. Group M remains the only HIV group that has established epidemics outside of 
Western Africa. 
The diseases caused by non-Group M HIV-1 strains are more difficult to classify due to 
the small numbers of infections documented relative to Group M. The most prevalent of 
these groups is Group O, with almost a million documented infections since its 
identification in Belgium in 1990 [55]. Almost all Group O infections are restricted to West 
Africa, particularly Cameroon.  The incidence of Group O infections has been steadily 
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declining since its identification, even as the numbers of Group M infections continued to 
rise in the same areas [56]. Group O disease largely mimics Group M infections though 
with reduced rates of tropism switching and mother-to-child transmissions. There are also 
increased numbers of elite controllers (patients who, without treatment, do not progress to 
AIDS) and patients who develop broadly neutralizing antibodies as a result of Group O 
infections relative to M [57, 58]. All of these factors likely contribute to a documented 
slower progression to AIDS in Group O infections [59].  
Group N and P infections are very rare, fewer than 20 Group N and 5 Group P infections 
have been recorded. Perhaps due to this rarity these cases are closely documented, however 
no concrete conclusions can be drawn about their disease progression. Case reports of 
Group N virus infections resemble the disease caused by Group M. Mother-to-child Group 
N transmissions have been documented, suggesting a far higher likelihood than other non-
Group M infections [51, 53]. Infections with Group N and M viruses typically require 
phylogenetic testing in order to differentiate due to the similarity in disease at early 
timepoints. Trajectories of CD4+ cell loss do not significantly differ between Group M and 
N infections and many of the same comorbidities and AIDS-defining-illnesses have been 
recorded [51-54, 75]. All of these measurements of disease progression are only available 
for the ~20 patients with Group N infections and could easily be skewed by population and 
selection biases. Group P, while capable of causing AIDS, appears to be the least 
pathogenic of the HIV-1 groups [50]. However, it is important to note that the very small 
numbers of infections make these conclusions impossible to validate [60]. 
1.5. Group M Diversity 
The origins of HIV-1 Group M infections have been traced by Sharp and Hahn to a small 
region of southeastern Cameroon within the Congo Basin [77]. Hahn and Sharp compared 
SIV strains isolated from chimpanzee feces from across Central and Western Africa using 
next-generation sequencing technologies [3, 25, 27, 28]. From this study they identified 
the location of the SIV strain, that of the Central Chimpanzee, which most resembled HIV-
1 Group M, likely the location the virus established within a human host. While the first 
decades of human transmission of HIV-1 Group M were sluggish, an epidemiological 
threshold appears to have been passed in the 1950s that led to rapid increases in 
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transmission [13, 80]. Hypotheses have been generated to explain this threshold, including 
adaptation of the HIV-1 accessory genes nef and vpu [81]. The same epidemiological 
threshold has not been reached by HIV-2 or other HIV-1 groups despite a similar early 
trajectory. The increased transmission and global spread led to massive diversification 
within Group M, yielding 9 viral subtypes: named A-D, F-H, J and K [82]. These subtypes 
can differ by up to 35% of the nucleotide sequence and are heterogeneously distributed 
globally [82-84]. Within each subtype, genetic variability is still quite significant, ranging 
from 8-17%. Subtypes A and F each contain distinct variants, termed sub-subtypes, though 
these variants differ enough to be considered unique subtypes by themselves (18-34% 
nucleotide divergence). Subtype A is broken into sub-subtypes A1, A2, A3, A4 and A6 
while subtype F is differentiated into sub-subtypes F1 and F2. Circulating recombinant 
forms (CRFs) and unique recombinant forms (URFs) can also form when a single patient 
is infected with multiple subtypes simultaneously, allowing the viral genome to recombine. 
As of 2018 there are 96 identified CRFs in HIV-1 and one in HIV-2. 
Conspicuously, HIV-1 Group M subtype nomenclature omits subtypes E and I. These 
subtypes, referred to as “problematic”, were identified as distinct through incomplete 
sequencing alignments [85]. When more complete sequencing was performed on the 
samples, these subtypes were found to be recombinants including either subtype A or 
numerous other Group M subtypes. For accuracy, subtype E was renamed circulating 
recombinant form AE (CRF01_AE), while subtype I was renamed circulating recombinant 
form complex (CRF04_cpx). 
1.6. Group M Geographic Distribution 
After crossing an epidemiological threshold in the 1950s, HIV-1 Group M diversified 
greatly, primarily due to the very high mutation and replication rates coupled with large 
numbers of newly infected individuals [76]. During this period the virus spread out of 
Central and Western Africa. Dating the epidemic in South Africa suggests a subtype C 
founder entered the population in approximately 1960 (+/- 8 years) [86]. Currently, South 
Africa routinely has one of the highest HIV infection rates in the world and is almost 
exclusively subtype C. Many published studies of the South African epidemic demonstrate 
that the virus has spread much more rapidly in the same time period relative to Central 
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Africa, where there is a greater diversity of circulating HIV subtypes circulating [86]. 
Recently, subtype C viruses have spread into China and India and appear poised to expand 
further in many countries in Southeast Asia [87, 88]. 
Establishment of a subtype B virus from Central Africa in Haiti in ~1964 led to the first 
epidemic in North America [89]. Sequencing of samples of known HIV+ individuals from 
the mid-1970s demonstrated a clear link between Haiti subtype B viruses and the first 
infection in the United States in New York City (dated to ~1970) [90-92]. In both Haiti and 
the United States, the epidemic doubling time is placed at about one year (0.86-1.12) 
suggesting extremely rapid expansion. The most likely theories about the arrival of HIV in 
the Caribbean involve missionaries returning to Haiti from Congo in the 1960s and future 
dissemination to Hispaniola, the Dominican Republic, and, eventually, the United States 
[89]. There also exist many legends about the introduction of subtype B into the United 
States and its early spread, typically involving a flight attendant patient zero, none of which 
are substantiated by facts [93]. Following its introduction, subtype B quickly became the 
dominant HIV subtype in not only North America and the Caribbean but also in South 
America, Europe and Australia. HIV phylogenies show subtype B is a recent divergence, 
likely pushed further by geographic evolutionary pressures and founder effects. This 
recency manifests in the short branch distance between subtypes B and D, making them 
the most closely related of the Group M subtypes, about 7% nucleotide distance in the pol 
gene [80].  
The predominance of subtype B in North America has led to a disproportionate focus in 
research funding and efforts even though fewer than 11% of individuals living with HIV 
globally harbor a subtype B virus [84]. The disease caused by subtype B provides almost 
all estimates of “time to AIDS” used by clinicians worldwide, approximately 8 years in the 
absence of treatment. This disease has been noted to be significantly more aggressive than 
most other HIV groups and subtypes, but exactly to what degree remains controversial [94, 
95]. Sub-Saharan Africa, the region with the greatest number of infected individuals, is the 
source of all ancestral HIV diversity. While this region still contains the greatest viral 
diversity, it is ironically generally devoid of subtype B infections, despite clear evidence 
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of its origin in Kinshasa, Zaire [89]. This region currently primarily contains infections of 
subtypes A, C and D [5, 96].  
1.7. Modern Epidemic and Research 
In 1981, Acquired Immune Deficiency Syndrome (AIDS) was documented for the first 
time. A series of patients presenting to hospitals across the United States displayed 
opportunistic lung infections, particularly Pneumocystis carinii pneumonia, and highly 
aggressive soft tissue cancer, Kaposi’s sarcoma, previously only seen in severely 
immunocompromised individuals [97, 98]. Now, clinical AIDS is defined by the World 
Health Organization (WHO) and the American Centers for Disease Control (CDC) as 
either a CD4+ T-Cell count below 200 cells/mL in the circulation, a T-cell percentage of 
total lymphocytes below 14%, or the presence of one or more of the 20 AIDS-defining-
illnesses. In order to validate the AIDS diagnosis, a patient must test positively for anti-
HIV antibodies, known as seroconversion [99]. 
In 1983 the etiological agent of AIDS was identified independently by Drs. Luc 
Montagnier and Robert Gallo, a retrovirus originally branded the lymphadenopathy 
associated virus (LAV by Montagnier) or human T-lymphotropic virus type 3 (HTLV-III 
by Gallo), later renamed the human immunodeficiency virus (HIV) [100-102]. Prior to the 
identification of HIV, no other lentivirus caused disease in humans. Identifying HIV as the 
causative agent of AIDS finally provided a research target. Since 1983, 22 single drugs and 
several multi-drug therapies have been approved by the U.S. Food and Drug 
Administration (FDA), targeting multiple steps of the HIV replication cycle. New methods 
of preventing infection have been developed including microbicides and pre-exposure 
prophylactic drugs. Unfortunately, resistance mutations have been identified, at least in the 
laboratory, to each of these drugs individually [103]. Two drug regimens targeting 
independent steps in the replication cycle historically have been overwhelmed by HIV 
mutation rates and develop resistance mutations to both drugs, though new combinations 
may overcome this block [104]. For now, however, HIV positive patients’ regimens must 




In the search of a cure, there have been four international vaccine efficacy trials which 
administered Env protein based vaccines to thousands of people around the world [105]. 
Each of the first three trials failed, perhaps most spectacularly in the HVTN-502 study (or 
“STEP study”) which increased the risk of infection in recipients. The final trial, RV144 
or the “Thai trial”, combined lessons from each of the previously failed vaccines, 
combining different Env immunogens to develop non-neutralizing and cellular immune 
responses in its recipients. The results of the trial were promising, showing a 31% reduction 
in the incidence of HIV in those vaccinated relative to controls [106]. Despite being the 
most successful HIV vaccine trial, the efficacy remained too low for widespread 
deployment and the results have been dissected and hotly debated, even before they were 
fully released. While many researchers had concerns with funding allocation, some 
epidemiologists raised significant concerns about selective patient exclusion during the 
final analyses, which were necessary for statistical significance [107].  
1.8. HIV Genome, Viral Structure and Replication 
The HIV genome is relatively small, even for viruses, at 10kb, varying slightly depending 
on the viral strain (Figure 1.2A). Structural proteins are encoded by the gag gene on the 5’ 
end of the genome, enzymatic proteins encoded in the pol gene, while the env gene encodes 
the structural Env protein, which is required for viral entry. Efficient viral protein 
production requires the activator proteins Rev and Tat which promote transcription and 
transport of mRNAs out of the nucleus. The remaining genes, vif, vpr, vpu, and nef are 
grouped together and called accessory genes. None of the accessory genes have enzymatic 
or structural functions, and most exist to antagonize cellular resistance factors. 
The process of HIV infecting a susceptible and permissive cell are classified into distinct 
steps: 1) attachment and entry, 2) reverse transcription, 3) integration, 4) transcription and 
translation, 5) assembly and packaging, and 6) budding, release and maturation (Figure 
1.3). Each of these steps are now targetable with different classes of antiretrovirals, though 





Figure 1.2 A) HIV-1 Genome organization. Rows show reading frames with HXB2 
nucleotide numbering shown below. Individual protein product abbreviations are denoted 
below, gene names denoted above. Inset shows the env gene coding sequence with HXB2 
nucleotide numbering. Variable regions and major features are labeled. 
B) Assembled HIV-1 Virion Structure. The assembled viral particle consists of a Gag 
matrix (MA) protein lattice with embedded env proteins (gp120 and gp41) protruding from 
a host-derived membrane. The ribonucleic acid genome is contained within a Gag capsid 
(CA) protein core. The interior of the viral core contains Protease, Tat, and Integrase with 
Reverse Transcriptase (RT) and Nucelocapsid (NC) proteins in association with the RNA. 
C) HIV-1 Env is comprised of a heterotrimer consisting of external gp120 and 
transmembrane gp41 subunits. Gp120 contains a series of variable loops around its outer 
surface and is heavily glycosylated. These variable regions interact with host cell proteins, 
particularly the entry receptors CD4 and, in sexual transmissions, CCR5. Gp41 contains 
two heptad repeats, a fusion peptide that inserts into the host cell membrane and a viral 
membrane transmembrane region.  
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1.8.1. Attachment and Entry 
The first stage of HIV infection is viral entry, which comprises attachment, receptor and 
coreceptor binding, membrane fusion and capsid/genome release into the cytoplasm. These 
steps are mediated by the HIV Env glycoprotein, the only viral protein exposed on the 
external surface of the virion. In order to evade the host immune system, Env is heavily 
glycosylated and must undergo a series of conformational changes during the viral entry 
process in order to expose the residues capable of binding and fusing with the host cell 
[108].  
The mature Env protein is heterotrimeric, consisting of three outer surface gp120 subunits 
and three transmembrane gp41 subunits (Figure 1.2C). Gp120 is composed of a bridging 
sheet linking an inner and outer domain. Notably, the inner domain contains both the N 
and C-termini pointing inwards towards gp41 [109]. The inner domain consists of a 5 
stranded β-sandwich and a two strand two helix bundle which are formed from the 
conserved regions of gp120 (C1 to C5) [109, 110]. Five highly variable regions (V1 to V5) 
extend outwards from the inner domain, making up the gp120 outer domain [111], forming 
loops that interact with extracellular host cell proteins, and mediating conformational 
changes and membrane fusion. The gp41 subunit is composed of a cytoplasmic tail, a 
transmembrane region, a membrane proximal external region (MPER) and two 
complementary heptad repeat regions (HR1 and HR2). These subunits, gp120 and gp41, 
are translated together as a gp160 precursor and are subsequently proteolytically cleaved 
at the cell surface. Following processing, noncovalent interactions are formed to hold these 
glycoproteins together as heterodimeric subunits. Trimers of these subunits, also called 
envelope spikes, are then reinternalized and trafficked to sites of viral assembly where they 
bind structural Gag matrices.  
The first interaction between a CD4+ T-cell and a viral particle involves non-specific 
electrostatic interactions between the sugar residues of the HIV Env gp120 glycoprotein 
with a number of host cell receptors, including the transmembrane receptor α4β7 Integrin 
[112]. These nonspecific interactions concentrate the number of viral particles at the cell 
surface, facilitating the interaction between the CD4 attachment receptor and the CD4 
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binding site (CD4bs) of gp120 (Figure 1.3.1). This binding site is highly conserved and the 
target of numerous identified neutralizing antibodies. Conservation at this site has also 
rendered this an attractive candidate for drug design, however CD4 mimetics and other so-
called attachment inhibitors have largely failed during clinical trials [113]. The only FDA 
approved antiretroviral that prevents viral attachment is Enfuvirtide (EFV or T20), 
marketed as Fuzeon. EFV has largely fallen out of regular use due to the rapid development 
of drug resistance mutations in the virus [114]. 
Isothermal titration microcalorimetry has demonstrated that binding of the CD4 receptor 
induces gross changes in both the exposed loops, including the V3 loop and the coreceptor 
binding site, as well as within the protein core. These studies also suggest that before 
binding to CD4, the viral envelope is capable of existing in multiple different 
conformations, between open and closed, with roughly equal free energy [115]. Following 
engagement with the CD4 receptor, the free energy of the system drops precipitously and 
locks the Env protein into an open state. This state exposes more of the V3 loop and allows 
the virus to bind its coreceptor (Figure 1.3.2). Although over fourteen different 
transmembrane receptors have been shown to support HIV infection in CD4+ cell lines, 
only CCR5 and CXCR4 have been shown to act as coreceptors in vivo [116-118]. 
Coreceptor binding initiates further conformational changes in the envelope, permitting the 
insertion of the gp41 fusion peptide into the cellular membrane (Figure 1.3.3). Through 
intermediate gp41 structural rearrangements, a fusion pore develops the viral and host cell 
membranes mix (Figure 1.3.4). The capsid core structure, containing the viral genome, is 








Figure 1.3) The process of HIV entry into a target cell is divided into four main events: 1) attachment to a host cell via the CD4 receptor 
engaging with the CD4bs of the HIV Env, 2) binding to a seven transmembrane chemokine coreceptor, typically CCR5 during sexual 
transmission, 3) fusion peptide insertion into the host cell membrane, and finally, 4) fusion of the viral and cellular membranes.
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1.8.2. Reverse Transcription 
The defining trait of retroviruses is the conversion of their single stranded RNA (ssRNA) 
genome into a double-stranded DNA (dsDNA) viral genome via the process of reverse 
transcription (Figure 1.4.3). The reverse transcriptase (RT) enzyme, encoded in the pol 
gene, is a DNA polymerase with both RNA-dependent and DNA-dependent activities. RT 
also has an associated ribonuclease H (RNaseH) with degradation activity of RNA in RNA-
DNA duplexes. Reverse transcription occurs in the cytosol and requires an RNA primer to 
initiate polymerization from the ssRNA genome template. In the case of HIV-1, a specific 
host tRNA serves as this primer and binds to an 18 nucleotide region known as the primer 
binding site (PBS) near the 5’ end of the genome (Figure 1.2A). This tRNA is incorporated 
into budding virions and some primer extension occurs prior to viral entry [119].  
Upon binding to the PBS, polymerization of minus (-) strand DNA proceeds towards the 
5’ end of the genome. Digestion of the genomic RNA by RNaseH frees this short ssDNA, 
known as minus strand strong stop DNA, which then hybridizes with the 3’ end of the 
genome via a short repeat region of homology. DNA synthesis proceeds along the 
remaining length of RNA genome in a 3’ to 5’ direction. RNase H leaves a region of RNA 
in the env coding region known as the poly-purine tract (PPT). The PPT serves as a primer 
for positive-strand DNA synthesis which proceeds in a 5’ to 3’ manner using the minus-
strand DNA as template. A second strand transfer event occurs where the positive-strand 
DNA binds to the minus-strand DNA at the PBS region which becomes present in both 
DNAs. Second strand DNA synthesis completes through bidirectional synthesis by the 
circular binding of the minus-strand to the positive-strand DNA. The double-stranded DNA 
product of reverse transcription contains identical regions at the 5’ and 3’ ends termed the 
long terminal repeats (LTR). These regions are essential for integration and mRNA 
transcription and contain the enhancer, promoter, transcription initiation, transcription 
termination and polyadenylation signals [120].  
1.8.3. Integration 
Following reverse transcription, the newly synthesized viral dsDNA must be imported into 
the cell nucleus for integration into the host chromosome. This is accomplished through 
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the formation of the pre-integration complex (PIC), a complex of host and viral proteins 
that actively transport the dsDNA into the cell nucleus. The PIC consists of the HIV viral 
dsDNA, the integrase (IN) enzyme, the viral Vpr protein, matrix protein, and host cellular 
factors. Due to the size of the PIC complex, it cannot passively transfer from the cell 
cytoplasm into the nucleus but must be actively carried into the nucleus through a nuclear 
import pathway fueled by a RanGTP gradient (Figure 1.4.4 & 1.4.5). Nuclear localization 
signals, found in matrix, vpr, and integrase, recruit nuclear importin proteins to the PIC. 
This active nuclear transport process permits HIV infection of non-dividing cells such as 
macrophages [121]. 
The process of integration initiates with a reaction known as 3’-end processing. The 
integrase enzyme cleaves off two nucleotides from the 3’ ends of both strands of linear 
viral DNA in a staggered manner, resulting in non-blunt ends. The 3’ recessed ends of viral 
DNA bind with the cleaved cellular DNA in a strand transfer event. Integration is 
completed when the gaps between the integrated viral DNA and cellular DNA are filled in 
by cellular repair enzymes. Once integrated, the viral DNA is referred to as “proviral” DNA 
[122].  
1.8.4. Transcription and Translation 
Following successful integration into the host chromosome, the proviral DNA is used as a 
template for the synthesis of viral RNAs which encode the necessary structural, enzymatic, 
and regulatory proteins for the production of progeny virus. The cellular machinery is 
utilized for the transcription of viral RNAs, RNA-splicing, and nuclear export. 
Basal transcriptional activity from the HIV LTR promoter is very poor. However, the Tat 
protein is delivered to the entering virion and produced from a small number of RNA 
transcripts generated early in infection [123]. Tat potentiates a positive feedback 
mechanism promoting high level HIV mRNA transcription. Tat binds to a transactivation 
response (TAR) element, a cis-acting RNA element that forms a stable stem-loop structure 
located downstream of the transcription initiation site [124]. The Tat-TAR interaction 
promotes the recruitment of a multicomponent kinase complex termed P-TEFb or positive 
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transcriptional elongation factor b [125]. P-TEFb activates RNA polymerase II, promoting 
processive mRNA elongation (Figure 1.4.6). 
Three major groups of RNA transcription products are produced from the proviral DNA: 
1) unspliced RNAs, 2) partially spliced mRNAs, and 3) multiply spliced mRNAs. The 
unspliced RNAs serve as genomic RNA for packaging in progeny virions and encode the 
Gag and Pol proteins. Partially spliced mRNAs encode the Env, Vif, Vpu and Vpr proteins 
while short, multiply spliced mRNAs encode the Rev, Tat, and Nef proteins. Differential 
splicing patterns can result in as many as thirty or more unique mRNA transcripts being 
produced [126]. 
Most cellular mRNAs are fully spliced prior to leaving the nucleus. However, HIV 
replication requires that partially and unspliced RNAs are transported out of the nucleus to 
the cytoplasm. In order to overcome this dilemma, the Rev protein (regulator of expression 
of viral proteins) binds to unspliced viral RNAs and shuttles them out of the nucleus. Rev 
binds to a cis-acting RNA element known as the rev-response element (RRE) located in 
the env gene. The RRE is a series of highly structured stem loops found in all unspliced 
and partially spliced viral RNAs [127]. Multiple rev proteins bind to the RRE and form a 
complex capable of interacting with the nuclear export machinery. Rev shuttles the 
unspliced or partially spliced RNAs to the cytoplasm and return to the nucleus by way of 
its nuclear localization signal. Once in the cytoplasm, viral protein synthesis from mRNA 
transcripts ensues through normal cellular translational machinery. 
1.8.5. Assembly and Packaging 
Production of Gag and Pol proteins promotes assembly of new virus particles at the plasma 
membrane. The matrix (MA) domain of Gag, which is located at the N-terminus of the p55 
precursor protein, is cotranslationally modified by the addition of myristic acid. Mutational 
studies suggest that a positively charged face of MA interacts with negatively charged 
phospholipids of the plasma membrane, stabilizing membrane binding [128]. 
In addition to associating with the plasma membrane, Gag must also participate in Gag-
Gag and Gag-RNA interactions. The Gag-Gag interaction is thought to involve multiple 
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regions of the precursor to form a matrix along the cell membrane [129]. In tandem, 
interactions between NC and a cis-acting element located 5’ of the gag initiation site known 
as the major packaging signal, or Ψ-site, mediate the incorporation of genomic RNA into 
virus particles. The envelope precursor protein, gp160, is synthesized in the endoplasmic 
reticulum (ER) and translocated into the ER lumen by means of an N-terminal signal 
peptide comprised of approximately the first thirty amino acids of the polyprotein. In the 
lumen, gp160 folds, disulfide bonds are formed, the protein is glycosylated, and 
oligomerizes to form trimers. After gp160 is properly folded and trimerized, it is 
transported to the Golgi complex where the polyprotein is cleaved by cellular proteases 
into the gp120 and gp41 subunits. The gp41 subunit is anchored to membrane and 
noncovalently associates with gp120. The envelope complex is trafficked to the plasma 
membrane through the secretory pathway. Mutational studies indicate that the MA domain 
of gag promotes envelope incorporation into budding virions through an interaction with 
the cytosolic tail of gp41 [130]. 
1.8.6. Viral Budding, Release, and Maturation 
Accumulation of Gag and associated RNA at the plasma membrane enhances the final 
stage of virion assembly known as budding. A proline rich domain at the C-terminus of 
Gag known as p6 encodes a small protein that promotes viral particle release from the 
plasma membrane [131]. Multiple studies have indicated a connection between the 
endosomal sorting pathway and the viral budding process. The observation that p6 interacts 
with a component of the ESCRT-I complex (endosomal sorting complex required for 
transport) further points to the importance of the endosomal sorting pathway in virion 
release [132].  
A cellular defense mechanism to prevent release and maturation of budded virus particles 
involves a cellular factor, Tetherin, which physically tethers budding virus particles to the 
cell membrane. These nascent particles are subject to internalization through endocytic 
pathways. While it has been known for some time that the accessory protein Vpu promotes 
release of virus particle [133], it has only recently been demonstrated that Vpu does so 
through antagonization of Tetherin [134]. 
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Shortly after virus release from the membrane, the protease enzyme cleaves the Gag and 
Pol precursors into the mature proteins. Once released, the structural proteins induce 
rearrangements in the virion morphology in a process known as maturation. Mature virions 
contain a conical shaped core encapsulating the RNA genome. Immature virions are not 
capable of establishing productive infections and thus maturation is a requirement for 
infectious particle production [135]. 
1.9. HIV Disease  
While modern medicine can reduce HIV replication to undetectable levels, in the absence 
of treatment HIV+ people living with HIV undergo a predictable progression of disease. 
Key features of the disease, such as the amount of infectious virus in the circulation (known 
as viral load), transmission efficiency, time to the onset of AIDS, serious HIV-related 
complications, and viral fitness, can be compared to quantify relative pathogenicity 
between strains.  
1.9.1. HIV Transmission 
HIV transmissions between humans are classified into several possible routes: sexual 
intercourse (both anal and vaginal for both partners), intravenous drug use (IVDU), 
Mother-to-Child (MTC) during pregnancy or delivery, accidental inoculation with 
contaminated bodily fluids (typically in health care workers) or during organ 
transplantation [136]. The most prevalent pathway for transmission is sexual but other 
modes may play a larger role in individual epidemics, like that of IVDU transmission in 
the former Soviet republics [137, 138]. Regardless of route, transmitted virus undergoes an 
immense genetic bottleneck, typically with a single viral variant causing infection in the 
recipient [139-143]. In those rare instances in which more than one viral variant is 
transmitted, patients experience a more rapid disease progression and reduced time to the 
onset of AIDS. This bottleneck has significant consequences for viral replication, as the 
transmitted-founder virus, or the virus establishing the new infection [144]. The most 
apparent of these consequences is the near universal utilization of the CCR5 chemokine 
coreceptor and reduced replicative fitness in the new host [145].  
  




Figure 1.4) The major steps of HIV replication: 1) Viral attachment to nonspecific extracellular receptors, 2) Specific viral interactions 
with CD4 (red) and a chemokine receptor (typically CCR5 in green) that leads to release of the viral capsid into the cytoplasm, 3) 
Reverse Transcription of the RNA viral genome into a DNA proviral genome, 4) Import of the pre-integration complex (PIC), 5) 
Integration of the DNA provirus into the host genome, 6) Viral transcription and translation generating viral proteins and full length 
RNA genomes, 7) Viral assembly at the cell surface, 8) Budding of the progeny virus and 9) Maturation into fully infectious new virions. 
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Many transmissions of HIV occur during the early phases before symptoms are displayed 
and without knowledge of the infected party’s status. Large scale testing efforts have been 
implemented globally, but have limits since diagnosing HIV can be prone to challenges 
and false-negative results [146, 147]. The long periods of asymptomatic infection during 
HIV disease amplify these challenges and are responsible for the relatively poor rates of 
HIV diagnosis. Of the 37 million people living with HIV, about 25% do not know that they 
are infected [1]. These numbers are thought to be even higher in Eastern and Southern 
Africa, the regions with the greatest HIV/AIDS burden. 
1.9.2. Acute HIV Infection 
The progression of HIV infection in the typical patient is classified into two phases, Acute 
and Chronic, each with their own associated symptoms, CD4+ T-cell responses and viral 
load dynamics. The Acute/Early phase, also called acute HIV infection (AHI), is classified 
as the period between viral transmission and stable viremia following the viral set point. 
Researchers frequently define the conclusion of this phase in terms of months post-
infection, however the exact number of months can vary between 2 and 4 [148]. 
Immediately following transmission, within the first 2 weeks, the host innate immune 
system is largely overwhelmed by the rapid replication rate of the virus and mutations that 
evade host immune responses. Viral loads in the patient’s circulation can spike to 107 
copies per mL and flu-like symptoms are common, however the precise symptoms vary 
depending on the viral strain and host genetics [149, 150]. Typically, this fever is described 
as resembling mononucleosis, with mainly minor symptoms including fatigue, headache 
and swollen lymph nodes, though meningoencephalitis and other serious complications 
have been observed [151]. Acute viremia can last up to several weeks before declining due 
to the host adaptive immune system [152]. Seroconversion, or the detection of anti-HIV 
antibodies in the patients’ circulation, typically occurs within the first 2 weeks following 
infection [153]. Most antibodies produced during this disease phase have epitopes that 
target the structural protein Gag and are non-neutralizing. Despite the inability to neutralize 
virus, these antibodies are very important markers for disease progression and their titers 
are one of the most reliable markers of pathogenesis [154]. The latent HIV reservoir, long-
lived memory T-cells containing integrated but not actively transcribed provirus, is also 
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established within AHI. Even when antiretroviral therapy is implemented within 3 days of 
virus exposure, the size and decay rate of the latent reservoir remains unaffected [155], 
though its T-cell subset makeup shifts away from central memory populations and towards 
resting memory T-cells [156, 157]. Both the size and makeup of the latent reservoir are 
impacted by viral subtype and have significant implications for treatment, disease 
progression, and long-term patient outcome [158-161].  
Many clinical measurements during AHI have been associated with either slower or more 
rapid disease progression. Peak viremia immediately following infection and viral load at 
the set point have both been implicated as predictors of CD4+ T-cell loss [41, 162, 163]. 
Unfortunately, the reproducibility of these results is inconsistent and multiple other studies 
have found no association between disease progression and AHI measurements, 
particularly when compared across different viral and host populations [164, 165]. These 
conflicts illustrate the difficulties predicting and evaluating disease progression in natural 
cohorts due to patient and virus variability.  
1.9.3. Chronic HIV Infection 
Chronic HIV infection typically refers to HIV disease after AHI, or the period of disease 
after the viral load set point. The set point represents an equilibrium between viral 
replication and the host immune system. This post-set point disease is typically called the 
asymptomatic phase of infection, which is marked by clinical latency of the disease. Viral 
loads are reduced relative to the other phases of infection due to suppression by the host 
innate and adaptive immune system. The asymptomatic phase of HIV disease progression 
may not display any outward symptoms of infection, but many of the defining processes 
of immunodeficiency occur during this phase [99]. Despite viral loads remaining low 
during the initial months following AHI, viral fitness and diversity increase rapidly [29, 
166, 167]. This is possible due to the sustained viral replication in lymphoid tissue even 
during the asymptomatic phase of infection [168]. Viral replication is also sustained even 
during ART [169-171], suggesting the viral replication and the symptoms of 
immunodeficiency are not inextricably linked. This continued replication may be one of 
the leading causes of drug resistance in patients who maintain high levels of drug 
adherence. 
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The asymptomatic phase of HIV infection is the longest phase of HIV disease. Since there 
are typically few HIV-related symptoms, relatively few patients are aware that they have 
been infected. Studies have shown that while both early and late stage HIV infections are 
more transmissible, due to high circulating viral loads, most transmissions occur from a 
patient in the asymptomatic phase due to the greatly expanded time scale [172]. The 
asymptomatic phase typically lasts multiple years, even in the most aggressive of cases. 
CD4+ T-cells are gradually depleted in a near linear rate over this period. Since these cells 
are necessary for survival and proliferation signals to other immune cells, their depletion 
leads to widespread immune system collapse, permitting opportunistic infections and rare 
cancers with an associated infectious agent etiology to be observed. Most patients 
experience one or several AIDS-related symptoms which include chronic wasting, 
diarrhea, swollen lymph nodes, skin lesions or rashes, oral sores, neurological 
complications, fatigue, fever and night sweats [173, 174]. The underlying driver of these 
symptoms is the broad inflammation and immune activation perennially experienced by 
HIV patients.  
1.9.4. HIV Disease Cellular Biology 
HIV disease has been characterized extensively over the decades following its emergence. 
The virus is able to compromise the host immune system due to its capacity to infect and 
deplete a number of immune cell types, primarily CD4+ or “helper" T-cells [175-178], 
though the virus can also infect macrophages and dendritic cells, albeit less productively 
[179]. The infection of CD4 T-cells eventually begins a multifaceted path to 
immunodeficiency related to cell death of directly infected cells [180-182], bystander cell 
apoptosis [183, 184], long-term immune activation [185-187] and impaired T-cell function 
[188-190]. As the disease progresses, the CD4+ T-cell population is gradually depleted. It 
has been documented that depletion occurs in particular T-cell subsets, namely the memory 
populations, and T-cells with HIV specific T-cell receptors (TCRs) [191-193]. These 
memory T-cells are a heterogeneous population of both effector memory and central 
memory T-cells. Effector memory T-cells (CD45R0+/CCR7-) are more differentiated, 
home to peripheral tissues, and can generate more effector memory cells in-vitro. Central 
memory T-cells (CD45R0+/CCR7+) are able to self-renew and reside in primary lymphoid 
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organs. Depletion of these populations is directly responsible for many of the characteristic 
symptoms associated with HIV disease and AIDS.  
The principal drivers of CD4+ T-cell loss in HIV patients has been subject to much 
investigation, but many facets remain mysterious. Key discoveries in the field 
demonstrated that the loss of CD4+ cells is centered in the lymphoid organs of the gut with 
other local sites of replication including the lymph nodes [194]. Serving as a primary site 
of viral replication, lymphoid organs undergo a progressive degradation of their structures 
[168]. The lymphoid tissue degradation, as well as persistent inflammation, leads to the 
characteristic “leaky gut” in chronically infected HIV patients [194]. Disruption of the 
structure of the digestive tract leads to further inflammation and bacterial translocation into 
the patient circulation, a vicious cycle that drives immune cell loss, particularly the cells 
that are resident in the nearby lymphoid organs (Figure 1.5). Live animal imaging in 
primate models has further validated lymphoid tissues as hotspots of viral replication, but 
it is still unclear what molecular mechanisms push these infected cells towards death [195]. 
Recent discoveries have pointed towards infected cells undergoing pyroptosis, a caspase-
1 mediated, highly inflammatory form of cell death [196]. Other studies responding to this 
discovery suggested apoptosis, T-cell mediated clearance and viral cytopathic effects as 
the most important drivers of CD4+ T-cell loss [197, 198].  
Bystander effects, or the death of uninfected, neighboring cells, has also been noted as a 
primary cause of death in lymph nodes during HIV and SIV infections [199]. These 
uninfected T-cells die via apoptosis, a caspase-3 mediated death pathway, that limits the 
release of inflammatory signals. The rates of uninfected cells undergoing apoptosis remains 
unaffected by the number of CD8+ T-cells, or cytotoxic T-lymphocytes (CTLs), suggesting 
that the death is caused by signals released by nearby infected cells, namely inflammatory 
cytokines [183]. During these same experiments, researchers also noted that productively 
infected cells were not necessarily dying after producing virus. Instead, a balance between 
latent and activated states causes these cells to persist [199]. These results suggest that the 
depletion of CD4 T-cells during HIV disease has been largely misunderstood, and that CTL 
responses and inflammatory cytokine signals drive the death of uninfected cells while the 
cytopathic effects of HIV are minimal. CTLs induce apoptosis via the extrinsic pathway, 
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typically via engagement of Fas, TNF or TRAIL with their cognate receptors, to actively 
clear infected cells [200]. CTL response breadth, as well as the absence of CTL escape 
mutations, have been identified numerous times as predictors of HIV disease severity and 
the likelihood of viral control [201-205].  
Finally, T-cells undergo a process of activation and expansion followed by contraction via 
apoptosis in response to T-cell receptor (TCR) activation with their cognate antigen in the 
context of MHC class II. HIV, being a highly inflammatory disease releasing huge amounts 
of antigen, causes broad inflammatory responses throughout the body, activating immune 
cells. The T-cells that activate in response will eventually undergo apoptosis or, in a 
minority, will become long-lived, memory T-cells. The extent and intensity of chronic 
immune activation strongly correlates with the timing of AIDS and CD4+ T-cell depletion 
[185, 186, 194, 206].  
Early experiments with HIV identified that these viruses require an activated cell to 
replicate [207]. Access to chromatin is necessary for the integration process which is only 
freed upon T-cell activation and active transcription. The long-lived memory T-cell 
population has a lower threshold for activation, making these cells ideal targets for HIV 
infection [208]. The effector memory subset (CD4+/CD45R0+/CCR7-) migrate to the 
periphery of the infected patient, homing to sites of inflammation, and likely encountering 
virus. Upon infection these memory cells can return to a quiescent state, forming the latent 
reservoir of HIV [209, 210]. This reservoir is what renders HIV incurable, due to its rapid 
formation after infection and the extremely long half-life of memory T-cells [171, 211].  
1.9.5. Clinical Measurements of Disease Progression  
HIV disease severity is typically quantified through a few clinical markers and diagnostic 
tests. The most classic of these is viral load, or the number of viral particles in a patient’s 
circulation, measured as copies per milliliter of blood. The test uses quantitative PCR to 
measure the number of copies of the non-integrated HIV RNA genome that are present in 
a sample. The development of this test was groundbreaking for its sensitivity in the 
diagnosis of HIV infection and drug regimen effectiveness, detecting as few as 50 RNA 
copies per mL of blood. Immediately clinicians and researchers identified both cumulative 
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viral load, or viral load at the set point closely associates with the timing to the onset of 
AIDS [41, 49, 160, 163, 212]. Recent investigations have identified many additional factors 
which may skew viral load for patient prognosis in some rare instances, particularly when 
concerning diverse HIV-1 isolates [160, 164]. 
Many host behavioral and genetic factors also exacerbate HIV disease progression. Stress, 
mental illness, drug and alcohol use, sexual behaviors, vitamin deficiencies, co-infections, 
rates of T-cell exhaustion, susceptibility to chronic inflammation, circulating cytokine 
levels, and other viral and host genotypes have all been implicated in driving rapid disease 
progression in different cohorts [163, 166, 213-236]. It is important to note, however, that 
almost all of these factors have also been found not to have an impact on disease 
progression in other cohorts/studies (e.g. alcohol and drug use in [237]). Many of these 
associations are likely population specific and lack the human diversity in the study group 
to properly control for host genotype. 
Some host human leukocyte antigen (HLA) alleles, encoding for major histocompatibility 
complex class I (MHC class 1) appear protective against HIV disease progression [238]. 
In particular HLA-B variants 57, 27 and 81 (HLA-B*57, HLA B*27 and HLA-B*81) are 
commonly associated with stable CD4+ cell counts, slow disease progression, and lower 
viral loads [239]. These alleles are non-homogenously spread across the globe. For 
example, in Africa, HLA-B*57 is found frequently in some regions of Africa (e.g. Zambia 
and South Africa) and at a low prevalence in other regions (e.g. Uganda and Zimbabwe) 
[240]. In populations in which HIV is less prevalent, these HLA variants are likely selected 
against due to their associations with many autoimmune disorders [241, 242]. 
Perhaps the most impactful host factor in determining HIV disease progression is the CCR5 
gene itself. Discovered in 1996, a 32 base pair deletion creating a premature stop codon in 
CCR5 generates a nonfunctional receptor that HIV is unable to bind to [243]. Since 
engagement with a chemokine coreceptor is essential for HIV entry, individuals that are 
homozygous for the Δ32 mutation are resistant to infection by CCR5-tropic viruses. Since 
CCR5-tropic viruses make up nearly all transmitted viral strains, these individuals have 
been documented to resist HIV infection even after repeated, high-risk exposures. 
   30 
    
However, rare instances have been observed in which CXCR4-tropic viruses can infect 
Δ32 homozygotes [244]. Individuals who are heterozygous for the mutation, possessing 
both full length and truncated versions of the CCR5 gene are semi-resistant to HIV 
infection, with reductions in infection rates near 50%. Researchers soon identified the 
mechanism of this partial inhibition; due to the required dimerization of CCR5 receptors 
while being transported to the cell surface. A truncated copy of the CCR5 receptor is unable 
to dimerize, thus greatly reducing cell surface CCR5, rendering the T-cells in these patients 
largely non-permissive [245]. Additionally, upon infection, heterozygotes progress to 
AIDS more slowly, delaying its onset by about 2-3 years relative to homozygous wildtype 
CCR5 patients [246, 247].  
While the Δ32 mutation is highly advantageous in preventing or limiting HIV infection, it 
remains a relatively rare allele. Depending on ethnicity, heterozygotes make up about 10% 
of the population in Europe, the continent with the highest frequency (about 1% 
homozygotes). This rate varies depending on ethnic background within Europe, with the 
highest levels of the mutation identified in people of Finnish descent (16% heterozygotes) 
and the lowest in Sardinian people (4% heterozygotes) [248]. All other continents have 
significantly lower rates of the mutation. The origins of the Δ32 mutation are hotly debated 
but appear to be recent and linked to reductions in pathogenicity of other human diseases, 
namely the bubonic plague (Yersinia pestis) or smallpox [249]. Conversely, individuals 
with Δ32 mutations also appear to be at greater risk of infection or mortality from 
flaviviruses, demonstrating the positive and negative selection dynamics on this allele [250, 
251]. 
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Figure 1.5) Summary of HIV Pathogenesis. Red lines represent CD4 T-cell counts per mL of blood in the circulation (solid red) and 
CD4 T-cell density in the lymphoid tissues (dashed line) over the course of infection. HIV viral load (black solid line) is also shown in 
infectious units per mL of blood (limit of detection at about 102 infectious units) with major disease features labelled.  
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1.10. Group M Subtype Pathogenesis 
Infections by different HIV Group M subtypes have long been considered to differ in 
pathogenicity, however exactly why and to what degree remains poorly understood. A 
series of epidemiological studies report differing patterns in the rates of disease progression 
and disease severity across Group M subtypes [252-258]. Unfortunately, the patterns 
suggested by each study directly contradict others, and seem to be swamped by 
confounding variables, poor controls, and conclusions that are not adequately supported by 
the data. 
The laboratory of Dr. Eric Arts has published direct comparisons of the relative replicative 
fitness via primary viral competition assays across all Group M subtypes (Figure 1.6) as 
well as between Groups M, N, O and HIV-2 (Figure 1.7) [255, 256]. Replicative fitness, in 
this sense, refers to a virus’s ability to replicate in a given environment. During these 
competitions, a single culture of primary activated CD4+ cells is infected with equal 
amounts of two viruses of differing groups or subtypes. These infections progress through 
multiple rounds of replication before viral nucleic acid is isolated and sequenced using 
high-throughput, next-generation sequencing (NGS) technology [255-257]. These data 
demonstrate the greatly reduced (up to 1,000 fold) replicative fitness of subtype C relative 
to subtypes A, B and D (Figure 1.6C).  
Intragroup competitions also show that subtype C clones more closely cluster with HIV-2 
isolates than with other Group M subtypes (Figure 1.7D). The well characterized reduction 
in pathogenic capacity of HIV-2 viruses strongly suggests similarly slow rates of disease 
progression during subtype C infections [39-41]. It has also been observed in subtype B 
infections that a greater proportion of untreated, infected individuals that do not progress 
to AIDS (Elite controllers) are infected with less fit viruses [259, 260]. These data highlight 
the direct effect of viral replicative fitness on patient disease progression and outcome. 
Elite controllers have also been found to harbor viruses with envelope proteins that interact 
with their cell surface receptors with low affinity and therefore infect cells with greatly 
reduced efficiency [261]. These results demonstrate a direct link between viral entry 
kinetics, fitness and viral suppression. However, these studies are unequipped to associate 
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reductions in viral fitness with pathogenicity and rates of disease progression in non-elite 
controlling patients. 
While uncommon, a few experimental explorations of HIV-1 Group M subtype 
pathogenicity have been previously published. The earliest of these investigations suffered 
from errors of convenience recruiting all HIV+ patients available in a given study site [94]. 
These recruitment tactics were typically recognized as less than ideal but were necessary 
to generate the statistical power necessary to tease apart an interaction as complex as 
immune system failure and HIV disease progression. The flaw in this study design is based 
around calculations of the time of infection based on clinical measurements like viral load 
and CD4+ cell counts. The variability due to host and environmental factors makes these 
estimates heavily biased, far outweighing any subtler effects of viral genotype. 
Other studies, while properly controlling for date of infection, failed to generate the 
necessary statistical power for robust analyses. In a study published in the Journal of 
Infectious Disease in 1999, Kanki et al. recruited all registered sex workers in Dakar, 
Senegal for biannual HIV monitoring (study ran from 1985-1997). Of the nearly 2000 
women enrolled in the study, 81 seroconverted during the study period and 11 of those 
reached clinical AIDS, defined as CD4 T-Cell counts below 200/mL. The study concluded 
that subtype C displayed a rapid disease progression simply because 3 of the 4 enrolled 
patients infected with subtype C viruses reached clinical AIDS during follow-up, their only 
measure of disease progression. Subtype A, the most represented subtype among 
seroconverters in the study, showed an eight-fold decrease in the likelihood of reaching 
clinical AIDS relative to non-A subtypes. This finding was soon refuted by multiple studies 
in Europe and Thailand showing either no difference in disease progression between 
subtypes or increased rates of pathogenesis in subtypes A and CRF01_AE relative to 
subtype B. Most recently, analyses in the Rakai cohort in rural Uganda demonstrated rapid 
disease progression in patients infected with subtype D relative to all other subtypes in the 
region. The rapid disease progression by subtypes B and D are the most pronounced and 
frequently reported, while subtypes A and C are typically considered less aggressive. These 
findings, like most studies quantifying disease progression, are still actively debated [94]. 
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1.11. Thesis Overview and Rationale 
1.11.1. Chapter 2 – Infecting HIV-1 Subtype Predicts Disease 
Progression in Women of Sub-Saharan Africa  
The broader HIV diversity, that is comparisons between HIV-1 and 2 and between the 
groups of HIV-1, has clear implications in disease progression. This differential 
pathogenicity has largely relegated non-HIV-1 Group M infections to small regions of 
Africa and limited the numbers of transmissions. What is unclear however, is whether the 
genetic diversity within Group M confers a similar range of disease progressions, what that 
pattern is, and how it impacts the cellular replicative cycle of HIV. Previous work has 
shown that this diversity manifests in a distinct pattern of replicative fitness in which 
subtype D and A outcompete subtype C in activated PBMCs. While low replicative fitness 
has been linked to viral control, there are no published direct measurements of the rate of 
CD4+ T-cell loss between multiple Group M subtypes in a single human population.  
Herein we seek to explore the role of HIV-1 Group M diversity on the diseases they cause, 
whether there is a continued link to viral replicative fitness, and whether the association 
with viral attachment and cellular entry hold when modelling CD4+ T-cell declines. In 
response to other published work we will also investigate viral load dynamics over the 
study period, specifically how diversity may impact circulating viral levels in both acute 
and chronic phases of disease.  
Cellular entry, the first stage of viral replication, is most closely linked with replicative 
fitness, but has not been directly implicated in severity of HIV disease. We will use three 
novel assays to interrogate viral rates of cell entry, affinity for the CD4 receptor, and 
induction of multi-cell fusion. 
Despite decades of research, the diversity of HIV-1 Group M around the world is rarely 
considered. Viruses of subtype B from North America makes up nearly all published work. 
Subtype diversity clearly will impact cure strategies, testing efforts, antiretroviral 
prioritization and will direct future spread of the pandemic.  
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1.11.2. Chapter 3 - HIV-1 Group M subtypes deplete memory and 
naive T-cell populations at different rates 
Previous investigations into CD4+ T-cell decline will be expanded to interrogate the 
dynamics of specific subsets with a focus on long-lived memory populations. Flow 
cytometry separations of archived cohort samples will be used to measure CD4+ and CD8+ 
T-cell dynamics, as well as CD8+ cell patterns of activation. These memory populations, 
when infected, allow for HIV to outlast even the best treatment regimens and rapidly 
rebound upon cessation. The role of HIV-1 Group M diversity on memory T-cell depletion 
has not been explored and will be a key determinant in the success of future cure efforts. 
These analyses seek to identify T-cell populations that are differentially depleted between 
subtypes, highlighting the differences in pathogenicity identified in Chapter 2.  
Finally, in response to other published work, we will examine different measurements of 
pathogenicity, that is time to unenrollment from the cohort as a proxy for the time to clinical 
AIDS. This methodology has been utilized previously in reporting contradictory findings 
to our own. We will use a Kaplan Meier estimator to track unenrollment based on infecting 
HIV-1 Group M subtype and statistically compare between groups. 
The future of HIV research will be disproportionately focused on memory T-cell subsets. 
These populations harbor integrated provirus for decades, evading combined antiretroviral 
therapy (cART). If they are to be eradicated, it is critical to understand the scope of the 
global challenge. Most measurements of memory subsets only focus on subtype B viruses 
while we will use a diverse group of viruses from Uganda and Zimbabwe to compare 
pathogenicity.  




Figure 1.6) Ex vivo replicative fitness derived from pairwise competitions between HIV 
Group M subtypes (A) Each CCR5 tropic primary isolate was competed against all of the 
other CCR5 tropic isolates. (B) Each CXCR4 tropic isolate was competed against all of the 
other CXCR4 tropic isolates. Fitness differences for the pairwise competitions were 
determined based on relative quantities of viral nucleic acid isolated post competition. 
Green boxes represent competitions in which subtype C was outcompeted by a non-subtype 
C isolate while Red boxes represent subtype C outcompeting non-subtype C isolates. (C) 
Results from the above matrices plotted by a given isolates replicative fitness calculated 
from all competitions. The lower left quadrant represents the least fit viruses while the 
upper right quadrant represents the most fit. Figure adapted with permission from [255]. 
C 
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Figure 1.7) Mean relative fitness values (0=less fit, 2=more fit) for intratype/intragroup 
and intertype/intergroup competitions in PBMCs involving both CCR5 and CXCR4 tropic 
(A) HIV-1 group M, (B) group O and (C) HIV-2 primary isolates. (D) Intertype/intergroup 
versus intratype/intragroup mean relative fitness of all CCR5 isolates. Clustering 
represents viruses of similar fitness, with the most fit viruses in the top right quadrant and 
the least fit viruses in the lower left quadrant. Figure adapted with permission from [256]. 
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Chapter 2   
Infecting HIV-1 Subtype Predicts Disease Progression 
in Women of Sub-Saharan Africa 
2.1 Background 
Human immunodeficiency virus type 1 emerged in the human population from the Congo 
River basin shortly after the turn of the 19th century following an established zoonotic 
jump of simian immunodeficiency virus from Pan troglodytes troglodytes [1]. Sixty to 
seventy years of deforestation, exploitation, and urbanization likely led to evolution, 
adaptation, and prevalence of HIV in the human host as well as the eventual spread of HIV 
across Africa [2]. Distribution of HIV-1 across the globe over the past 30-35 years can still 
be traced to founder events with primordial HIV strains from sub-Saharan Africa [1-3]. 
Our knowledge of HIV-1 disease and treatment is still largely limited to the 3 million 
subtype B HIV-1 infections that dominate North America and Europe despite the mixture 
of HIV-1 subtype A, C, D, and circulating and unique recombinant forms (CRFs and URFs) 
responsible for 30 million historic and 28 million current infections in sub-Saharan Africa 
[1-3].   
The extreme genetic diversity between HIV-1 subtypes has phenotypic consequences in 
vitro including differential HIV-1 mRNA transcriptional control [4, 5], protease activity 
[6], integration site selection [7], MHC class I downregulation [8], and entry efficiency [9]. 
Overall, subtype C HIV-1 isolates display a significant reduction in replicative fitness in 
primary human CD4+ T-cells relative to HIV-1 isolates of any other subtype [10-12]. 
Despite these studies, comprehensive analyses on the natural history of non-subtype B HIV 
infections are still not available to guide treatment and prevention strategies in the >28 
million people currently living with HIV-1 in sub-Saharan Africa. A few longitudinal and 
cross-sectional studies on patients in sub-Saharan Africa have suggested that subtype A, 
C, D and URFs/CRFs HIV-1 infections could have different disease courses and treatment 
outcomes as compared to subtype B infected populations [13-19]. Faster progression to 
AIDS and higher treatment failures were observed in subtype D versus subtype A 
infections [15, 16, 20].  
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From 1999-2003, over 4,400 HIV-negative women in Uganda and Zimbabwe were 
enrolled in the Hormonal Contraception and the Risk of HIV Acquisition (HC-HIV) Study 
[21], during which 303 women were identified with incident HIV infection and participated 
in the Hormonal Contraception and HIV-1 Genital Shedding and Disease Progression 
among Women with Primary HIV Infection (GS) Study [22-24]. The 76 subtype A, 177 
subtype C, 31 subtype D and two URF HIV infected women (286 of 303 women) were 
followed for an average of 5 years, currently the largest natural history cohort of non-
subtype B infections. Consistent with WHO recommendations at the time of the study, 
treatment was provided when HIV-infected participants reached CD4 cell counts below 
200/ml on two consecutive tests or were diagnosed with stage IV or advanced III disease 
(WHO Classification). Antiretroviral therapy (ART) was not yet routinely available in 
these countries during the study period, however, the study team felt that it was ethically 
imperative to provide treatment to women participating in the project and committed study 
resources to provide that treatment. This study was designed to monitor immunologic and 
virologic parameters and to compare these biomarkers of disease progression to country of 
origin, contraceptive use, infecting subtype, and phenotypic properties of the virus.  
2.2 Methods 
2.2.1 Participants and clinical tests 
A complete description of the Ugandan and Zimbabwean participants is provided in the 
Supplementary methods and previously described [23, 24].  Women who became HIV 
infected while participating in the Hormonal Contraception and Risk of HIV Acquisition 
Study in Uganda and Zimbabwe [21] were enrolled upon primary HIV-1 infection into a 
subsequent study, the Hormonal Contraception and HIV-1 Genital Shedding and Disease 
Progression among Women with Primary HIV Infection (GS) Study [22-24]. Blood and 
cervical samples were collected every month for the first six months, then every three 
months for the first two years, and then every six months up to 9.5 years. Women who had 
CD4 lymphocyte counts of 200 cells/ml and/or who developed severe symptoms of HIV 
infection (WHO clinical stage IV or advanced stage III disease) were offered combination 
ART (cART) and trimethoprim-sulfamethoxazole (for prophylaxis against bacterial 
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infections and Pneumocystis jeroveci pneumonia). In addition, information was collected 
at every visit related to changes in sociodemographic information, sexual behavior, 
sexually transmitted and reproductive tract infections, opportunistic infections, and diet.  
Following primary infection, 112 Uganda and 174 Zimbabwean women were followed for 
an average 1,826 and 1,899 days (respectively) (Supplementary Figure 2.1) for a maximum 
of 3,453 days (9 ½ years) (Supplementary Figure 2.1). Antiretroviral treatment was 
initiated in 23% of the women in both countries but 100 days sooner on average in the 
Ugandan versus Zimbabwean women (1,458 versus 1,558 days) (Supplementary Figure 
2.1). As described [22], cervical and plasma viral loads were determined with the Roche 
Amplicor HIV-1 Monitor Test, version 1.5 using cryopreserved samples from visits from 
every three months. CD4 T-lymphocyte counts were determined by standard flow 
cytometry using FACSCalibur (Becton Dickinson, Sparks, MD, USA).  
2.2.2 Models to determine viral load increases and CD4 cell 
declines.  
A marginal model with the generalized estimating equation (GEE) approach including 
autoregressive error structures (accounting for repeated measurements on the same 
individual) was used to determine the plasma viral load changes and compare rates of CD4 
cell decline [22]. Multivariable analyses included demographic, sexual, contraceptive and 
medical history data and underwent stepwise model simplification with a significance 
threshold of p≤0.05. All analyses used Stata Version 14 (StataCorp LP, College Station, 
TX). 
2.2.3 DNA sequencing and subtyping.  
DNA was extracted from patient PBMC samples obtained at the seroconversion visit and 
every 3 months post HIV infection. Primers specific to the protease (PR) and polymerase 
regions of reverse transcriptase (RT), and C2-V3 envelope (env) coding regions were used 
to PCR 300, 800, and 450 nt regions as described [12] in a Virology Quality Assurance 
(VQA) certified laboratory in Kampala, Uganda [22]. The HIV-1 sequences were edited 
using BioEdit v7.0.4 and PR-RT coding regions were uploaded into the Stanford 
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University HIV Drug resistance database (http://hivdb.stanford.edu) to obtain drug 
resistance profiles. Phylogenetic alignments were performed using maximum likelihood 
methods (MUSCLE [25]) and trees constructed using SEAVIEW 4 [26] and FigTree 1.4 
(http://tree.bio.ed.ac.uk/software/figtree/). Each participant PR, RT, and Env sequence was 
aligned to curated set of subtype A, B, C, D, G, and CRFs HIV-1 reference sequences 
(hiv.lanl.gov). 
2.2.4 Virus cloning and propagation 
The entire gp120 coding region and the extracellular domain of gp41 (referred to as Env 
DNA) was PCR amplified with the ENV REC primer set from PBMC DNA derived from 
the patient samples at the seroconversion visit. Briefly, pREC_nflΔenv/URA3 was 
linearized with SacII (Fermentas) and transformed into Saccharomyces cerevisiae MYA-
906 cells (ATCC) using lithium acetate along with Env PCR products [27]. Following 
homologous recombination, plasmids were extracted from the yeast cells growing on plates 
containing minimal media, 5-Fluoroorotic Acid (5-FOA) but lacking leucine.  The yeast 
derived plasmid DNA was then transformed into electrocompetent Escherichia coli Stbl4 
cells (Invitrogen) and amplified for high purity plasmid purification using the Qiagen 
midiprep kits.  Detailed procedures of the yeast recombination/gap repair for HIV-1 
cloning has been described [27].  The resulting pREC_nfl plasmid contains a subtype B 
NL4-3 backbone with the patient derived gp120/gp41 ecto coding region. This plasmid 
produces virus-like particles and can be used to access Env glycoprotein function and to 
measure the rate of host cell entry in virus [28] and cell-to-cell infections [29]. pREC_nfl 
(containing the patient derived Env gene) can also be co-transfected with pCMV_cplt 
complementing vector in 293T cells to produce replication-competent virus as describe and 
used for the studies on replicative fitness [27]. 
2.2.5 Reverse Transcriptase Assay 
To quantify viral particles, we utilized a previously published radioactive nucleotide 
incorporation assay to measure viral reverse transcriptase [262, 263]. Briefly, 10μL viral 
concentrates were added to a 96 well plate. 25μL RT buffer was added to each well of the 
plate (50 mM Tris-HCl (pH 7.8), 75 mM KCl, 2 mM DTT, 5 mM MgCl2, 5 μg of poly(rA) 
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per ml, 0.5% NP-40) and allowed to incubate for 10 minutes at room temperature. 1μL 
radiolabeled thymidine triphosphate is then added (10-mCi/ml [α-32P] TTP). Plates were 
then incubated at 37°C for 2 hours. The synthesized radioactive DNA is then blotted onto 
DEAE filter mats (Wallac) and dried on a hotplate. The mats are then washed in SSC buffer 
(x5) and 85% Ethanol (x2) and dried again to remove unbound radiation. Finally, these 
radioactive mats are placed in plastic bags and exposed on a cassette which are read on a 
Phosphimager (GE Storm 840). Quantification of radioactive spot intensity was done using 
ImageJ. A more detailed protocol is available in previous publications [262, 263]. 
2.2.6 Replicative fitness 
47 primary HIV-1 isolates of subtypes A (12), C (27), and D (8) derived from patients from 
cohorts from Europe, South America, Asia, and all regions of Africa were titered on PHA-
activated, IL2-treated PBMCs of HIV-negative donors using the standard Reed-Munch 
TCID50 determination [30] then competed against 25 subtype B HIV-1 in the same 
PBMCs. We also competed two reference subtype B HIV-1 isolates, B-QO and B-K44 
against chimeric viruses derived from the acute/early infection samples of 5 subtype A, 3 
subtype D, and 5 subtype C infections of this cohort.  The relative production of two viruses 
in each competition was measured by a radiolabeled heteroduplex tracking assays or using 
next generation sequencing [10-12]. Assay sensitivity is 100-fold differences in replicative 
fitness expressed as percentages.  
 
2.2.7 Cell-to-cell infections 
Veritrop involved the transfection (Fugene 6, Promega) of the pRECnfl constructs 
containing patient Envs into 6.5x104 HEK293T cells [29] then cultured for 8 hours. To 
synchronize Env engagement and cell fusion, the effector HEK293T cells were placed on 
ice before being spun onto 6.5x104 of U87 CD4+ CCR5+ target cells (500 x g for 5 minutes 
at 4°) transfected with a HIV tat-responsive luciferase plasmid (pDM128fluc).  Co-cultures 
were then brought to 37°C and allowed to form syncytia for 12 hours. Fully inhibitory 
concentrations of Enfuvirtide (3uM) were added at discrete time points (t=4, 4.75. 5.5, 6.25 
and 7 hours post combination) to replicates of each construct throughout this incubation to 
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stop fusion events. Medium was removed after 12 hours and the Bright-Glo Luciferase 
Assay System (Promega) was used to quantify luciferase production on a plate reader 
(Biotek Synergy 2). Drug treated cells were compared to untreated controls to calculate 
percent maximal fusion. Relative rates of fusion by Env subtype were statistically 
compared based on time required to reach 50% maximal fusion (ANOVA, STATA Version 
14, College Station, TX). 
2.2.8 Virus entry into host cells 
Cotransfection (Fugene 6, Promega) of the pMM310 plasmid (NIH AIDS Repository, cat 
#11444) with the pRECnfl patient constructs into 3.0x105 HEK293T producer cells 
generated viruses containing the HIV-1 accessory protein Vpr fused to E. coli β-lactamase 
(BlaM). The viruses were purified via ultracentrifugation and quantified using p24 ELISA 
(NCI Frederick Cancer Research and Development Center, AIDS Vaccine Program). 
1.5x104 U87-CD4-CCR5 cells were plated on black, clear-bottom plates and loaded with 
CCF2-AM dye (Live-BLAzer, ThermoFisher) for 60 minutes. The pRECnfl/BlaM viruses 
were added to the culture at a multiplicity of infection of 2. Cells were placed on a plate 
reader (Synergy 2, Bio-Tek) and virus entry was quantified every 15 minutes by comparing 
emission at 460nm (cleaved dye) relative to emission at 530nm (uncleaved dye) following 
excitation with a 405nm laser. Dye cleavage curves were normalized relative to cell-free 
and virus-free controls, means calculated for each subtype and statistically compared based 
on time required to reach 75% maximal viral entry (ANOVA, STATA Version 14, College 
Station). 
2.2.9 Competitive CD4 ELISA  
96-well plates were coated with Goat Anti-Human IgG Fc Ab 1:10,000 and 100µL was 
added per well. These plates coated overnight at 4°C. Following the incubation, the plates 
were washed three times with 0.05% Tween-20 (Sigma) in DPBS. 100µL of 10% FBS in 
DPBS was added to the plates to block and they were incubated at room temperature for 1 
hour. Washes were repeated. 100µL of IgG-anti-Fc antibodies at 0.2 μg/mL in DPBS were 
added to each well and incubated at room temperature for 1 hour. Washes were repeated. 
Blocking steps were repeated for 1 hour at room temperature. 100µL of CD4-Fc fusion 
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protein diluted in DPBS was added (20μg/mL) to all wells, followed by repeating wash 
steps. 50µl of purified virus was added in triplicate for 5 timepoints, 15 wells per sample. 
Plates were then sealed with plate seals and incubated overnight at 4°C. Following the 
incubation, wash steps were repeated. 100µL of soluble CD4 (sCD4) diluted in DPBS was 
added (20μg/mL) to all but the non-competed controls which received 100µL DPBS. 
Competitions incubated at 37°C for 4, 12, 24, and 48-hours post-addition of sCD4. Wells 
were washed with plain DPBS to remove unadhered virus and filled with 100µL DPBS to 
prevent desiccation. Once all competitions finished the DPBS was aspirated and each well 
received 25µL of lysis buffer and the quantitative reverse transcriptase assay was employed 
to measure remaining bound virus. Results from a subsample of these trials are shown in 
Supplementary Figure 2.6. To conserve reagents, future experiments would only use the 
24-hour timepoint, where differences between subtypes was found to be most pronounced. 
Comparisons between subtypes were made with ANOVA using Tukey multiple 
comparison tests, significance p<0.05. Schematic of the assay is shown in Figure 2.6A. 
2.3 Results 
2.3.1 Monitoring disease progression in the absence of 
treatment 
Newly infected Ugandan (N=112) and Zimbabwean (N=174) women, 71% (N=203) 
enrolled within 18 weeks of the infection date were followed for an average of 5.1 years 
up to 9.5 years in the absence of combination antiretroviral therapy (cART), initiated when 
CD4 cell counts dropped below 200/mm3 or concurrent counts below 300/mm3 
(Supplementary Figure 2.1). Complete sociodemographic, clinical chemistries, and other 
clinical data has been reported [22-24, 31]. 
Lower CD4 T-cell levels were reported in uninfected women and in our early infection 
cohort of Zimbabwean women as compared to Ugandan women [31]. Despite this 
difference between countries, declines in CD4 T-cells was 2-fold slower in the 
Zimbabwean women population than in the Ugandan women in the absence of treatment 
(Figure 2.1a&b) (GEE model; P<0.001). 
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Figure 2.1) The graphs around the map display the number of people living with HIV-1 between 1980 and¬¬ 2015 in the four UNAIDS 
Regions with the greatest number of infections as well as globally. The distribution of subtypes in 1990 and 2015 are shown in the inset 
pie graphs, scaled by the number of infections. Relative numbers of subtype C infections per UNAIDS Region are reported on the pie 
graphs and via red shading on the map. Data compiled from the World Health Organization, UNAIDS and published literature 
(References in Supplementary Files). 
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Virus levels at both the set point and all future time points in the plasma and endocervix 
did not significantly differ by country (Figure 2.2a) [22]. The cohort was also analyzed for 
rapid progressors (CD4 decline to below 200 cells/ml within 2 years of infection) and 
controllers/non-progressors (stable CD4 cell counts above 350 with viral loads <2000 
copies/ml in plasma for more than 3 years post-infection) in the absence of treatment. 
Approximately 7.4% (n=13) and 8.1% (n=9) were classified as rapid progressors in 
Zimbabwe and Uganda but controllers were observed in less than 3% (n=3) of Ugandan 
women versus 10% (n=18) of Zimbabwean women (Figure 2.1d). When rapid progressors 
and controllers were removed from the analyses, the CD4 declines were still significantly 
slower in Zimbabwean versus Ugandan women (P<0.001). As reported by numerous 
studies, the rate of CD4 decline is directly associated with HIV disease progression [1, 3]. 
2.3.2 Possible factors contributing to country-specific difference 
in disease progression 
To explain these differences in CD4 T-cell decline between countries, we analyzed 
numerous factors previously described as correlates of disease progression. Opportunistic 
infections and secondary infections (malaria, TB, various STIs) were not significantly 
different in the cohorts and each infection was treated accordingly upon diagnosis. Other 
factors such as diet, recurrent sexually transmitted diseases (chlamydia, trichomonas, 
HSV-2, bacterial vaginosis), smoking, sexual behavior, depomedroxyprogesterone acetate 
(DMPA) use, and combined oral contraceptives (COC) use did not show significant 
differences in HIV-1 disease progression between countries [22-24, 31, 32]. There may be 
a perceived difference in human genetics between the two countries that may explain this 
differential disease progression.  Our informed consent and institutional review board 
(IRB) approvals did not permit genetic testing in these patients.  These women self-
reported being members of the Shona tribe of Zimbabwe and Buganda tribe of Uganda 
which are both of Bantu origin which has the highest HLA diversity among humans as well 
as lower frequencies of protective HLA B*57 (3-5%) and B*27 alleles (<1%) [27, 33, 34] 
than in Caucasian populations (7.0 and 9.2%, respectively) (www.allelefrequencies.net/). 
Thus, it is unlikely that any of these genetic polymorphisms could explain the striking 
differences in CD4 decline between HIV-infected Ugandan and Zimbabwean women.  
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2.3.3 Infecting HIV-1 subtype correlates to disease progression 
The infecting HIV-1 isolates in these women were subtyped using the HIV-1 PR, RT and 
C2-V3 gp120 env coding regions (Supplementary Figure 2.2&3). As expected, the 
Ugandan women, all residing in Kampala, were predominantly infected with subtype A 
(68%, n=76) followed by subtype D (28%, n=31), 3 cases of subtype C, and 2 intersubtype 
A/D recombinants (Supplementary Figure 2.3a&b). All 174 Zimbabwean women were 
infected with HIV-1 subtype C. Based on the infecting subtype, women with subtype C 
HIV-1 infections had CD4 T-cell declines (-0.489 cells/week, GEE model) 2.5-fold and 
1.6-fold slower than with subtype D and A infections, respectively (-1.231 cells/week and 
-0.781 cells/week, GEE model) (Figure 2.1c). The faster CD4 T-cell declines in subtype D 
infections also resulted in more patients (45%, n = 14) requiring cART than in women 
infected with subtype A and C (28% and 32%) (Supplementary Figure 2.1b). Slow or non-
progression (defined as controllers) was not observed among the subtype D infected 
women as compared to the 4% (n=3) and 10% (n=18) in the subtype A and C infected 
women, respectively. In contrast, subtype A, D, and C infected women had similar 
frequencies of rapid progressors (8.5, 11, and 7.5%, respectively) (Figure 2.1d). Again, 
viral levels at set point (Figure 2.2c) in plasma or endocervical mucosa or in plasma during 
disease (Figure 2.2a,b,d,e&f) did not differ by subtype (statistical analyses in Figure 2.2g).  
To illustrate subtype-specific differences, CD4 T-cell and viral RNA levels were plotted 
for 9 subtype C controllers, 9 subtype C typical progressors, and 9 subtype D typical 
progressors (Figure 2.3) (subtype A, C, and D rapid, slow, and typical progressors are 
shown in Supplementary Figure 2.3). The controller status in subtype C infected patients 
is quite evident with less than 0.03 CD4 cells lost per week (based on all 13 controllers) 
(Figure 2.3a) as compared to the 0.48 lost per week (linear regression model or 0.49 
cells/week, GEE) in the 148 typical subtype C progressors (Figure 2.3b). This rate of CD4 
T-cell decline in subtype C is obviously slower than that observed in the typical subtype D 
(Figure 2.3c) and subtype A (Supplementary Figure 2.3) progressors (-1.0 and -0.60 CD4 
cell loss/week, respectively, linear regression). Viral load increases (following 
establishment of viral set point) were similar in all the subtype A, C, and D progressors 
(Figure 2.3d,e,f and Supplementary Figure 2.3) but viral loads remained the lowest in the 
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subtype C controllers with an actual decrease over time (-4 HIV-1 RNA copies/ml/week; 
Figure 2.3d).  
2.3.4 Phenotypic differences between HIV-1 subtypes 
For this study, we analyzed 143 published and 42 unpublished dual HIV-1 competitions 
involving 47 subtype A, D, and C HIV-1 isolates against 25 subtype B isolates (Figure 
2.4a&b). In these dual infection/competitions, absolute virus production can vary 100-fold 
in PBMCs of different human donors but the relative production (i.e. fitness) of one virus 
versus another typically varies less than 10% [10-12]. Subtype C HIV-1 isolates are clearly 
less fit in PBMCs than subtype A and D HIV-1 isolates (P<0.002) when competing against 
subtype B HIV-1 (Figure 2.4a). Subtype C viruses were not detected (i.e. 100-fold less fit) 
in 60% (n=74/123) of the competitions despite the fact that these same subtype C viruses 
were readily detected in mono-infections or competitions against other subtype C isolates 
[10-12]. These competitions of subtype A, C, and D versus subtype B HIV-1 suggest a 
fitness order of HIV-1 subtype B = D > A > C in human PBMC or primary CD4 T-cells 
(Figure 2.4) [10-12]. We have previously reported that the replicative fitness of primary 
HIV-1 isolates is dominated by the env gene and the rate of cell entry, i.e. the rate limiting 
step in HIV-1 replication [9, 11]. Five subtype A, 5 C, and 3 D HIV-1 env genes (from 13 
patients) derived from acute/early infection were used to produce chimeric virus (subtype 
B NL4-3 backbone) which were then competed against the B-Q0 and B-K44 subtype B 
reference viruses (Figure 2.4c&d, respectively). The subtype D Env chimeric viruses were 
able to compete with both the B-Q0 and B-K44 reference viruses whereas the subtype A 
Env chimeric viruses were less fit (Figure 2.4c&d). In contrast, subtype C Env chimeric 
viruses derived from acute/early infection had extremely low replicative fitness or were 
completely outcompeted by the B-K44 and B-Q0 reference viruses. Thus, both the HIV-1 
subtype C found at acute/early infection and in chronic disease are less fit than subtype A 
and D HIV-1 co-circulating in these Bantu populations.   
HIV-1 infection can be mediated by cell-to-cell virus transfer or by direct virus infection. 
We examined cell-to-cell infection using the more physiological Veritrop system where 
transfection of the pREC-nfl HIV-1 vector into 293T effector cells can produce HIV-1 
particles (non-infectious) and can mediate fusion with the U87.CD4.CCR5 target cell [28].  
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The absolute level of cell-to-cell HIV transmission was similar with 34 acute/early env 
genes in pREC-nfl over a 12 h incubation (Supplementary Figure 2.5). Cell-to-cell fusion 
kinetics was then measured using a time-of-drug-addition experiment where Enfuvirtide, 
an inhibitor of HIV-1 entry, was added at different times post effector/target cell co-
incubation (Figure 2.5a). Subtype C HIV-1 Env glycoproteins derived from acute/early 
infection mediated significantly slower rates of cell-to-cell HIV-1 infection than did 
subtype A (P<0.001) or subtype D (P<0.001) Env glycoproteins based on the T1/2 of 
Enfuvirtide inhibition.  
Next, we measured the rate of free virus entry into host cells (U87.CD4.CCR5) using these 
same 34 acute/early env genes in pREC-nfl. In this case, pREC-nfl was co-transfected with 
pMM310 BlaM-Vpr to produce HIV-1 particles harboring a Vpr-BlaM fusion protein 
(Figure 2.5b). Upon de novo infection, the HIV_nfl is fully capable of host cell entry which 
releases the Vpr-Beta-lactamase to cleave the fluorescent CCF2 dye and change fluorescent 
spectra [31] (Figure 2.5b). The rate of virus entry into host cells was the slowest with the 
16 HIV_nfl harboring the acute/early subtype C envelopes as compared to those carrying 
the subtype A (P<0.05) and subtype D envelopes (P<0.001) (Figure 2.5c&d).  
This cohort demonstrated large fitness reductions in the infecting subtype C viruses which 
correlated with reductions in entry efficiency. Work developing assays to clarify Group M 
virus entry rates and CD4 affinities in different CD4+ T-cell memory cell populations is 
ongoing. Preliminary data comparing CD4 attachment receptor affinity is shown below. 
These experiments were pursued to explore previous finding that HIV-1 Group M subtypes 
differ in their entry rates and rates of HIV induced cell-cell fusion. To clarify the stage of 
viral entry that differs most between subtypes, a novel competitive CD4 binding ELISA 
was used to quantify the first step of viral entry between viruses from the cohort (Figure 
2.6A). Initial experiments were used to establish a protocol and competition timepoints 
(Supplementary Figure 3.4). These explorations were used to set a 24-hour competition 
period to identify subtype differences. Significant differences after a 24-hour competition 
were found between subtypes C and D (p<0.05), and subtypes A and D (p<0.001, T-tests) 
(Figure 2.4B). Subtypes C and A did not appear to differ in their affinity for CD4. Subtype 
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D showed the greatest affinity for CD4, only losing about 8% of the bound virus when 
competed with sCD4. Subtypes A and C lost 30.5% and 48% of bound virus, respectively. 
2.4 Discussion 
By the 1980s, all the HIV-1 subtypes had emerged, were circulating and recombining in 
the Congo basin as well as spreading to neighboring countries/regions [1]. Various HIV-1 
subtypes were introduced in multiple geographic regions (South Africa, Zimbabwe, 
Brazil, India, etc) [3] by the late 1990s and yet, subtype C HIV-1 rose in prevalence 
faster than any other subtype in the heterosexual population (<10% in early 1990s to 
>50% today) (Arien et al., 2007) (Figure 2.1). We have previously reported that HIV-1 
subtype C isolates had lower replicative fitness in human T-cells and macrophages than 
other group M subtypes [10-12] but could only speculate that HIV-1 subtype C may 
cause slower disease progression [3]. Aside from regions in Brazil, Tanzania, and Kenya, 
HIV-1 subtype C typically dominates in regional pandemics and does not co-circulate at 
high frequencies with other HIV-1 subtypes in human populations [3]. As a consequence, 
comparing disease progression related to different HIV-1 subtype infections in a single 
country or region is very difficult. Thus, we screened for and recruited 300 AHIs in 
Ugandan and Zimbabwean women and then followed the natural history of these HIV 
infections for 5–9 years in the absence of treatment. With this cohort in Uganda and 
Zimbabwe, we have a population of only women, all of Bantu origin, all recruited within 
AHI (following heterosexual transmission), and finally, representing the subtype A, C 
and D HIV cohorts for sufficient statistical power to measure differences in disease 
progression. Independent statisticians at two different institutions (FHI 360 and Case 
  




Figure 2.2) CD4+ cell declines in HIV-1 infected Ugandan (n =112) and Zimbabwean 
women (n=174) during the natural course of disease. (a) The mean loss of CD4 cells per 
mm3 per week of infection in Ugandan and Zimbabwean women and (c) in those women 
infected with subtypes A, C, and D. (b) The percentage of rapid progressors and slow 
progressors/controllers in Ugandan and Zimbabwean women and (d) in those women 
infected with subtypes A, C, and D. Rapid progressors are defined as HIV-1 infected 
women with a drop to 200 CD4 cell counts/mm3 within 2 years of infection and sustained 
viral RNA loads greater than 2000 copies/ml. Slow progressors/controllers had viral RNA 
loads stable CD4 cell counts above 350 and viral loads < 2000 copies/ml in plasma for >3 
years. 
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Western Reserve University) analyzed the cohort data presented herein. The 2-fold 
difference in disease progression between these two countries was not attributable to diet, 
secondary/opportunistic infections, sexual habits, or age [24]. Of course, we could not 
screen for presence or absence of all pathogens, sociodemographic or tribal/population 
differences but the questionnaires administered by medical officers at each patient visit 
was extensive as was the tests for various clinical chemistries and other health indicators. 
Examples of the questionnaire are included in the attached Supplementary Files. We are 
currently interested in screening the microbiota in the vaginal tract of these women to 
assess possible difference which may be associated with disease progression but again, we 
do anticipate differences that segregate by country given the similar diet and diverse human 
genetics. Of all the parameters tested, only HIV-1 subtypes could clearly delineate 
differences in the rate of CD4 cell decline in blood. Infection with subtype C HIV-1 
resulted in the slowest declines in CD4 T-cell counts (0.489 cells/week) as compared to 
subtype A (0.781 cells/week) and then subtype D HIV-1 infection with the most rapid 
declines in CD4 T-cell counts (1.231 cells/week).  
Like other natural history cohorts, rapid disease progression was observed at a 7–9% 
frequency regardless of HIV-1 subtype but slow progressors/controllers appeared only in 
subtype A and C infections. The differential rates of CD4 T-cell declines (D N A N C) was 
still significant when rapid progressors and controllers were removed from the analyses. 
We have proposed that a combination of “good” host genetics (e.g. HLA B27 or B57) and 
infection with HIV of low replicative fitness may result in “elite” HIV control [35] i.e. a 
rare condition in Africa but closely approximated by the 13 subtype C infections with no 
declines in CD4 cell counts and b103 copies/ml of virus for N 5 years of infection (Figure 
2.3a & f). 
Based on previous human genetic studies across Africa [27, 33, 34, 36, 37] 
(www.allelefrequencies.net/), we now know that the Bantu population has the greatest 
genetic diversity of Homo sapiens. Low prevalence of “HIV protective” 
polymorphisms/alleles in the Shona and Buganda tribes (both Bantu) (e.g. <5% of 
CCR5Δ32, CCR2a 64I, HLA-B57 and B27) could not explain the dramatic differences in 
disease progression. Interestingly, there were no significant differences between countries 
    





Figure 2.3) Comparing disease progression in a subset of 56 women in Uganda and Zimbabwe infected by different subtypes. 
(a)(b)(c)(d)(e) CD4 cell counts/ml were plotted over time in subtype C infected women defined as slow progressors/controllers (a), as 
typical progressors (b), in subtype A infected women defined as slow progressors/controllers (c), as typical progressors (d), and in 
subtype D infected women defined as typical progressors (e). (f)(g)(h)(i)(j) Viral RNA loads in plasma of subtype C slow progressors, 
C typical progressors, A slow progressors, A typical progressors and D typical progressors, respectively. 
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or HIV-1 subtypes in the viral RNA levels at set point or over the course of infection. In 
our previous report using 188 patients from this cohort and with minimal analyses of follow 
up (b3 years), we observed slightly higher viral loads at set point in subtype C and D versus 
A infections (p=0.04, ANOVA) that has not held significance when expanding to the 286 
patients in this study [22]. Instead, expansion of the cohort size now showed a trend for 
lower viral load set points in subtype C infections versus A or D (Supplementary Figure 
2.3c). Regardless, it is again important to stress that we did not observe any significant 
differences in viral load during disease based on infection by specific HIV-1 subtype.  
Most studies examining disease progression in natural history cohorts are now impossible 
and unethical based on WHO guidelines for the initiation of cART in all HIV positive 
patients regardless of CD4 T-cells counts [38]. With the start of this study in 2000, we 
followed WHO/UNAIDS guidelines to treat with CD4 cell counts ≤200/ml which was 
controversial because few charities, governments, and international organizations (e.g. 
WHO, PEPFAR) had rolled out their treatment programs in Africa. During this ten-year 
cohort study, 33% of the participants received treatment at an average of 1,500 days post 
infection. Subtype D infected women were ~1.7-fold more likely to receive treatment than 
subtype A or C infected women. By modelling the rates of CD4 declines in this natural 
history cohort, the projected time to reach ≤200/ml or AIDS in these women was 1.3-fold 
longer with subtype C (estimated mean of 12.3 years) than A (9.5 years) and 2.0 fold longer 
with C than subtype D (6.2 years). Historical data of subtype B infections in North America 
and Europe suggest 6-8 years as an approximate time to reach AIDS (CD4 T-cells <200/ml) 
[39, 40] but there are no natural history cohorts from diagnosis (prior to treatment) to 
establish accurate estimates. Interestingly, despite different geographical regions, different 
human populations, and higher rates of parasitic and other infectious diseases, secondary 
and opportunistic infections in Uganda, infections with subtype B in North America and D 
in Uganda may have similar rates of CD4 T-cell declines and time to AIDS. Subtype B and 
D HIV-1 share the most sequence homology of all subtypes and multiple studies suggest 
that subtype B was a sub-branch and “member” of the subtype D super-cluster. Earlier 
reports have also described faster disease progression and reduced response to treatment in 
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East Africans infected with HIV-1 subtype D than subtype A [15, 16, 20].
 
Figure 2.4) Relative replicative fitness of HIV-1 subtype A, B, C, and D in human 
peripheral blood mononuclear cells. (a) 12 subtype A, 8 subtype D, and 27 subtype C HIV-
1 primary isolates were competed against 25 subtype B HIV-1 isolates in PHA-activated, 
IL2-treated PBMCs of HIV-negative donors in series of published and unpublished studies. 
All competitions in PBMCs involved the use of 0.001 infectious units of virus to 1 cell. 
The relative production of two viruses in each competition was measured by a radiolabeled 
heteroduplex tracking assays or using next generation sequencing10-12. Production of 
individual HIV-1 isolates in a dual infection (f0) divided by its initial proportion in the 
inoculum (i0) is referred to as the relative fitness (w = f0/i0). In this study, w is expressed 
as percent replication of the subtype A, C, or D HIV-1 isolates relative to subtype B HIV-
1. Assay sensitivity is 100-fold differences in replicative fitness. (b) The relative replicative 
fitness of the subtype B HIV-1 isolates in competition with the subtype A, C, and D HIV-
1 (the reciprocal of a). Symbols with thick outlines represent replicative fitness of the 
classified virus at greater than 100-fold or less than 0.01-fold to competitor virus. The 
shaded symbols represent the replicative fitness values of primary HIV-1 isolates. The 
open/white symbols represent the replicative fitness values of replication-competent 
chimeric viruses containing the env gene of a subtype A, C, or D virus within the NL4-3 
subtype B backbone. (c) and (d) Replicative fitness of chimeric viruses derived from env 
gene of 5 subtype A, 3 subtype D, and 5 subtype C AHI of this cohort. These 13 AHI 
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chimeric viruses were competed against the reference subtype B HIV-1 isolates, B-QO (c) 
and B-K44 (triplicate).  
HIV-1 subtype C isolates are less fit than subtype A which are both less fit than subtype B 
and D HIV-1 isolates, a finding established by over 2000 direct head-to-head dual virus 
competitions in primary CD4+ T-cells and macrophages from HIV-negative donors of 
different races/ethnicities [10-12]. These findings suggest a direct association between the 
replicative fitness of HIV-1 and subsequent disease progression.  In addition, the HIV-1 
env genes derived from 47 women with acute/early infections also showed that subtype C 
as compared to subtype A and D were slower in host cell entry by free virus and slower in 
cell-to-cell transfer of virus.  
In vitro assays of HIV Env engaging with cell surface receptors have also demonstrated a 
rate imbalance in the receptor/ligand interactions. Using the Affinofile system, a 
transformed cell type with manipulatable levels of surface CD4 and CCR5, the required 
receptor densities for infection have been quantified for diverse viral strains [264]. The 
results demonstrate that the affinity of the open confirmation of Env is much higher for 
CCR5 than the closed confirmation is for CD4. While future work should explore whether 
Group M subtype impacts CCR5 affinity, work in this manuscript began with the stage of 
viral entry that is the most rate-limiting.  
The first stages of HIV infection, those of attachment and cellular entry, have also been 
most associated with replicative fitness [265]. These correlations warrant investigations 
into the specific step of the entry process that confers this competitive advantage. Our 
initial experiments show that the attachment to CD4 receptors correlate with overall entry 
rates, patient disease progression and viral replicative fitness in this cohort. While there are 
still downstream stages of viral replication to explore, there appears to be little published 
variability in the rates of these steps. Future work will explore how variable entry rates, 
fusion dynamics, and induced apoptosis differ across the T-cell subsets investigated here. 
This will be accomplished using a flow cytometry model and HIV entry-responsive dye 
system. These observations, as well as reduced fusion and viral entry efficiency, suggest 
that infecting HIV-1 subtype may set the course of subsequent disease progression.  
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In summary, this largest natural history cohort of non-subtype B infected women revealed 
a significant difference in HIV-1 subtype virulence with ramifications for HIV-1 spread 
and treatment in the global epidemic. Women infected with HIV-1 subtype C progressed 
to AIDS at least 1.5-fold slower than women infected with subtype A or D.  Longer 
asymptomatic periods of a subtype C infection will lead to greater probability of 
transmission, especially among those discordant couples with unknown infection status 
(http://www.who.int/hiv/pub/progressreports/update2014/en/). Using human cervical and 
penile explant tissues, transmission “fitness” appears to be similar among most HIV-1 
subtypes [12, 41]. Thus, the expansion of HIV-1 subtype C infections in the global 
epidemic may be related to the low virulence of subtype C, resulting in long periods of 
asymptomatic periods, and leading to increased opportunity for heterosexual transmission 
over other HIV-1 subtypes. Ultimately, HIV-1 subtype C may be more “fit” in the human 
population based on low subtype virulence and potential high transmission efficiency due 
an protracted asymptomatic phase. 
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 Figure 2.5) Function, cell-
to-cell transmission 
efficiency and viral fusion 
of the Env glycoprotein 
derived from acute subtype 
A, C, and D HIV-1 
infections. The HIV-1 env 
gene of acute/early 
infections in Ugandan and 
Zimbabwean women was 
cloned into the pREC-nfl 
HIV-1 genomic vector by 
yeast-based 
recombination/gap repair 
as described. The function 
and co-receptor usage of 
the Env glycoprotein from 
these 14 subtype A, 4 
subtype D, and 16 subtype 
C acute/early infections 
was accessed using the 
Veritrop cell-to-cell fusion 
assay. None of the 34 Env 
produced in the context of 
virus-like particles (VLPs) 
could mediate cell fusion 
via the CXCR4 co-receptor 
within U87.CD4.CXCR4 
cells (below negative 
control and 1000 RLUs) 
(data below range of graph 
in (a)). (a) Cell-to-cell fusion between the U87.CD4.CCR5 target cells expressing Firefly 
Luciferase upon Tat/Rev-mediate expression from pDM1.1 and the 293T effector cells 
expressing the 34 Env glycoproteins in context with HIV-1 VLPs. The NL4-3 nfl VLPs 
are morphologically identical to wild type HIV but is incapable of reverse transcription and 
cannot induce luciferase expression in the target cells. (b) Schematic of the time-of-drug-
addition experiment using the Veritrop assay. 2 uM of Enfuvirtide was added at 30 min to 
10 hrs post incubation of the effector and target cells. (c) Box plot of the time to 50% 
inhibition by Enfuvirtide of cell-to-cell fusion mediated by 34 Env glycoproteins expressed 
in context with the HIV-1 VLPs. (c) Schematic of the viral fusion assay which can be 
monitored by HIV-1 carrying a BlaM-Vpr fusion protein that cleaves the CCF2 dye in 
target cells and changes the fluorescent spectrum. (d) Relative entry over time (0-600 min) 
into U87.CD4.CCR5 cells by the chimeric HIV nfl carrying the 14 subtype A, 4 subtype 
D, and 16 subtype C Env glycoproteins from acute/early infections. (e) Spectral shift curves 
and box plot of the time required for maximal virus entry into U87.CD4.CCR5 cells 
carrying the CCF2 dye. 
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Figure 2.6) CD4 binding strength via competitive ELISA between HIV-1 subtypes. A) 
Schematic of the assay 1) Plates were coated with anti-human-IgG-Fc antibody 2) CD4-Fc 
was then attached 3) HIV adheres to the CD4-Fc and 4) Is competed off the plate with free 
sCD4. Non-competed controls normalized input via Reverse Transcriptase Assay. Input 
virus was also normalized in the same way. B) Percentage of virus removed after 24 hours 
of competition with sCD4, smaller numbers suggest greater binding strength. Means 
compared via t-test, *p>0.05, ***p>0.001. n=23. 
 
  
    




Supplementary Figure 2.1) The follow up time period and time of cART initiation in the Ugandan and Zimbabwean women enrolled 
following acute/early infection. (a) The length of follow-up time for each HIV-infected woman by country and by HIV-1 subtype is 
shown in this box plot. The number of days of infection preceding the initiation of cART is also shown. cART was only initiated in 
those women with CD4 cell counts below 200 cells/ml and/or who developed severe symptoms of HIV infection (WHO clinical stage 
IV or advanced stage III disease). (b) The percentage of HIV-infected woman by country and by HIV-1 subtype that required cART 
during the study period. 
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Supplementary Figure 2.2) CD4+ cell declines in HIV-1 infected Ugandan (n =112) and Zimbabwean women (n=174) during the 
natural course of disease. (a) and (b) CD4 cell counts per mm3 as measured in whole blood by FACS Caliber in Ugandan and 
Zimbabwean women from AHI to 9 years post infection.  
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Supplementary Figure 2.3) Viral RNA loads in blood and cervix during HIV-1 infections. 
(a) and (b) Bulk viral RNA viral loads in the plasma of HIV-1 infected Ugandan (n =112) 
and Zimbabwean women (n=174) during the course of disease. (c) Viral RNA levels at set 
points in the plasma and endocervical swab samples of women from the different countries 
and infected by different subtypes (as determined by Loess procedure)22. (d)(e)(f) Bulk 
viral RNA loads in the plasma of patients infected with Subtype A, C and D HIV-1 
respectively. (g) Statistical significance of GEE models relating infecting HIV-1 subtype 





Supplementary Figure 2.4) The HIV-1 subtype classification based on the C2-V3 env 
nucleotide sequence. A 450 nt C2-V3 envelop (env) coding regions were amplified from 
patient samples and DNA sequenced (see Materials and Methods).  The HIV-1 sequences 
were edited using BioEdit v7.0.4, aligned using Neighbor joining (ClustalX43) and 
maximum likelihood methods (MUSCLE38). Neighbor joining and maximum likelihood 
trees were constructed with SEAVIEW 439 and visualized with FigTree 1.4 shown in this 





Supplementary Figure 2.5) The HIV-1 subtype classification based on the PR and RT 
nucleotide sequences. (a) 300 nt PR and (b) 800 nt RT sequence in the pol gene was PCR 
amplified from patient samples, aligned using Neighbor joining (ClustalX43) and maximum 
likelihood methods (MUSCLE38), and presented as trees in the figure. Two HIV-1 RT 
sequences from Ugandan women did not cluster with subtypes A, C, or D and were 
analyzed for possible intersubtype recombination using RIP and SimPlot 
(www.hiv.lanl.gov/content/sequence/HIV/HIVTools.html). (c) Patient 1-515-10526-4 was 







Supplementary Figure 2.6) Example Reverse Transcriptase Assay outputs for CD4 
competitive ELISA. This proof-of-concept experiment used timepoints of 12, 24 and 48 
hours of sCD4 competition to find the greatest separation in subtype binding strengths. 
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Chapter 3  
HIV-1 Group M subtypes selectively deplete memory 
and naive T-cell populations at different rates 
3.1 Introduction 
Rapidly upon infection, the Human Immunodeficiency Virus (HIV) establishes a 
transcriptionally silent, latent reservoir of integrated provirus [1]. This pool of infected 
cells is what renders HIV infections incurable and is so rapidly generated that even the best 
therapies, administered just days after seroconversion, do not prevent its formation [2, 3]. 
While most circulating cells are transient and have half-lives of a few days to weeks, the 
most concerning cells of the HIV reservoir are the CD4+ T-Cell memory subsets which 
confer immunological memory for decades [4]. The half-life of these cells is approximately 
44 months; estimates suggest remaining on antiretroviral therapy for 70+ years would be 
insufficient to clear this latent pool [5]. Therefore, the dynamics of infection and cellular 
death in these populations have profound implications for both the individual patient as 
well as global HIV eradication strategies.  
Integration of the viral genome into the host allows for the virus, even after years of 
suppression, to reactivate upon cessation of antiretroviral therapy [1, 6]. Modern 
combination antiretroviral therapy (cART) is capable of fully inhibiting viral replication to 
the limits of detection, but require lifelong adherence to a regimen of three drugs that may 
have pronounced side-effects and can shorten the patient’s lifespan [7-9]. Even with the 
success of antiretroviral treatment, only half of the HIV infected population receive cART 
and still another of the quarter of the 37 million infected do not know their status [10].  HIV 
related deaths have decreased to less than 1 million/year while the number of new 
infections remains relatively constant at nearly 2 million a year [10].  Thus, renewed efforts 
have focused in an HIV vaccine, due also in part to the successes of the RV144 vaccine 
trial. Vaccination strategies that educate the recipients immune system against HIV would 
be able to eradicate any reactivated infected cells. Unfortunately, in another cruel twist, the 




worldwide, is so vast that no monovalent vaccine would be capable of targeting every 
strain.  
This same HIV diversity in the epidemic confers differential drug resistance rates, 
transmission abilities, CD4+ T-cell depletion rates, and virulence [11-17]. Perhaps due to 
these differences, or other unexplored driver(s), HIV-1 Group M subtypes have spread at 
different rates around the world since the virus was identified in 1983 [18, 19]. Most 
apparently, subtype C has risen to be the most prevalent strain in the world, representing 
~55% of all HIV-1 infections. While other HIV-1 subtypes from Central Africa may have 
been introduced earlier, they appeared to have spread slower in many geographical regions. 
Subtypes A and D circulate in many of the same regions of Africa but only make up 10 
and 4% of all infections worldwide, respectively [18].  As described in the previous 
chapter, subtype C HIV-1 appears to replicate slower than subtype A and D in CD4+ T 
cells which is directly related to slower disease progression.  Of course, the administration 
of cART will halt disease progression regardless of the HIV-1 subtype responsible for 
infection.  However, there may be a differential rate of memory CD4+ T cell infection by 
these HIV-1 subtypes prior to treatment, which has implications for the size of the HIV 
reservoir during cART.  In this chapter we initiated studies to determine the relative 
infection and depletion of memory T-cell subsets in women infected with subtype A, C, 
and D prior to treatment. 
Previous work from our laboratory has demonstrated that infections with HIV-1 Group M 
subtype C viruses, relative to other Group M subtypes, have a prolonged time to the onset 
of clinical AIDS without differing in viral loads at set point or during chronic infection. 
These analyses extensively controlled for host and environmental factors that can skew 
measurements of disease progression, including coinfections (particularly Malaria and 
Tuberculosis), sexual habits, diet, and hormonal birth control use. However, despite these 
controls, some researchers raised questions about how these results align with other 
published work. Previously published investigations have suggested that subtype C 
infected patients quickly reach clinically defined AIDS (CD4+ T-cell counts below 200 




explore the differential disease progression between subtypes A, C, and D, focusing on the 
memory T-cell subsets.  
As HIV disease progresses, the canonical measure of pathogenesis is the rate of CD4+ T-
cell loss [20]. Differences in these rates have been associated with numerous viral and host 
traits, with broad implications for treatment and research. Confoundingly, researchers have 
noted that different T-cell populations have varying degrees of infectibility and rates of 
apoptosis. Central and effector memory T-cell populations are both more infectible by HIV 
than naive CD4+ T cells and have increased densities of CD4 and CCR5 entry receptors 
on their surface [21, 22]. Although HIV can gain entry, virus replication only occurs upon 
activation of any of these T cell subsets.  In general, the memory T-cell subsets are more 
commonly activated by common recall antigens (e.g. malaria and TB as well as the 
continual HIV replication) than naive T cells responding to novel antigens [23].  Thus, 
memory T cells are thought carry the greater burden of HIV replication.  Over the course 
of HIV disease, the CD4+ T-cell memory subsets may be depleted more quickly than other 
subsets due to direct infection and bystander apoptosis.   An important question remains 
whether HIV Group M subtypes deplete these populations at different rates. Most studies 
have measured differential T-cell subset infection in anatomical sites of viral replication, 
but this effect is also notable in the circulation.  
This also raises the question whether the differences in disease progression extend to the 
loss of T-cell memory subsets or if the memory subset decline is independent from disease 
progression. Most researchers associate differences in rates of cell death between T-cell 
subsets with receptor density on the surface, known to differ between memory T-cell 
populations [21, 24].  This may also suggest that the differences observed between HIV 
Group M subtypes may be due to differing affinities for these receptors. Downstream viral 
cytopathic effects (CPE), or even signaling through Env receptor binding, may compound 
over time to drive T-cell depletion. 
While the molecular causes of HIV induced cell-death have been explored at-length, it 
remains unclear how the vast diversity within Group M infections impacts which cells are 




In this manuscript we will investigate how Group M diversity, in particular subtypes A, C 
and D from Uganda and Zimbabwe, differentially deplete T-cell memory subsets.  
3.2 Methods 
3.2.1 Cohort 
A cohort of 303 number of HIV positive women from Uganda and Zimbabwe were 
monitored throughout their disease progression in the Genital Shedding Study (GS Study), 
as described previously (Section 2.2.1, [25-28]). Blood draws were taken at each visit for 
viral load titers and white blood cell counts. Over the course of the study, many of these 
aliquots were frozen at -80°C and stored for future analysis and a database was created of 
CD4, CD8 and viral load test results associated with each sample. A complete history of 
this cohort is available in Chapter 2, section 2.2.1 or published previously [25-29]. 
3.2.2 Archived Samples and Flow Cytometry 
Flow cytometry panels were run to quantify CD4+ and CD8+ memory T-cell populations 
on a subset of patient white blood cell samples. 69 patients who were enrolled in the study 
for a minimum of 1,000 days and had CD4 and CD8 T-cell counts documented from each 
visit had a total of 388 samples analyzed, an average of 5.6 timepoints per patient. These 
timepoints were selected to fall over the linear range of disease progression; at least 100 
days post-infection to avoid the set point. To quantify memory populations in these 
archived samples, isolated buffy coats were thawed, spun down and stained with a cocktail 
containing CD4-PerCP, CD45RO-FITC, and CCR7-PE or CD8-PerCP, CD45RO-FITC, 
CD38-PE, & HLA-DR-APC antibodies per manufacturers protocol. Cells were incubated, 
washed and run on an LSR-II (BD Biosciences). Relative numbers of each memory 
population were calculated by multiplying the proportion of cells in each gate (Figure 3.1) 
by the archived CD4 and CD8 cell counts in the study databases. All lymphocytes were 
gated by lymphocyte size using forward and side scatter. Gates described are Naïve CD4+ 
T-cells (CD4+/CD45RO-/CCR7+), Central Memory CD4+ T-cells 
(CD4+/CD45RO+/CCR7+), Effector Memory CD4+ T-cells (CD4+/CD45RO+/CCR7-), 






Figure 3.1) Flow cytometry gating strategy to differentiate memory subsets of CD4+ and 
CD8+ T-cells. From the left, lymphocyte gating using Forward and Side Scatter, CD4 and 
CD8 positivity using PerCP conjugated antibodies and memory subset quantification using 
either CCR7-PE and CD45RO-FITC for CD4+ cells or CD45RO-FITC and CD8-PerCP 





Markers of activation (HLA-DR and CD38) were also added to CD8+ T-cell Naive and 
Memory tubes (Figure 3.1 for quantification and gating). 
3.2.3 Models 
Marginal generalized estimating equation models were employed to associate viral 
diversity with changes in CD4+ T-cell populations, similarly to previous (See Section 
2.2.2). Patients codes were used as the subject level to control for varying numbers of 
observations per patient. Models were constructed by running univariate correlations 
between subtype groups and progressively adding variables. While data normality was 
checked, it is not strictly necessary in GEE models. Goodness of fit scores were compared 
when adding variables to the model to minimize residuals. Variables were excluded if they 
were both insignificant between subtype groups and failed to improve model fit [30]. Error 
structures were also compared. Autoregressive error structure (AR(1)) both improved 
model fit and most accurately represented the theory of CD4+ T-cell decline in the 
literature [31]. In the final model, T-cell counts over time, circulating viral load (RNA 
copies/mL), and country of origin were included. All analyses were done using STATA 
Version 14 (StataCorp LP, College Station, TX). 
3.2.4 Virus Cloning, Propagation and Purification 
Viral stocks from patients in the GS cohort were isolated from blood draws at each visit. 
Patient viruses from timepoints within 3 months of seroconversion were used in all in-vitro 
experiments. Patient Env DNAs in pREC_nfl vectors, lacking the 5’LTR, were generated 
(as described in Section 2.2.4). In these vectors the 5’LTR promoter is replaced with a 
CMV promoter to generate viral particles that can only infect for a single round but can be 
transfected with a vector containing the 5’LTR to reform infectious particles. Patient HIV 
isolated env genes were cloned in this way for 30 patients in the cohort that also had 
memory T-cell data collected. Virus particles were formed by transfecting into HEK-293T 
cells with Fugene 6 (Promega). 
Infectious particles from the GS study (full length patient virus) as well as reformed 




these studies. Viruses were propagated in U87*CD4*CCR5 cells (NIH AIDS Cat. No. 
4035) in DMEM with 15% fetal bovine serum, 1 µg/ml puromycin, 300 µg/ml G418, 
glutamine, and pen/strep. Infections were continued for 7 days and supernatant was 
purified and concentrated. Briefly, the supernatant was cleared of cellular debris by 
centrifugation at 3,000 RPM. Supernatant was then loaded into a syringe and filtered with 
a 0.45µm syringe filter into an Amicon Ultra 15 Filter Unit (100kDa filter, Millipore). 
Amicon tubes were spun in a bucket rotor centrifuge at 3,700 RPM for 12 minutes to pass 
supernatant through the filter. Using a pipette, the concentrated supernatant from the upper 
Amicon filter unit was transferred into a 1.5mL snap-cap tube and filled with DPBS 
(Sigma). Tubes were spun at 32,000g in a fixed rotor centrifuge for 1 hour at 4°C. 
Supernatant was discarded and viral pellets were resuspended in a small volume of DPBS. 
3.2.5 Kaplan Meier Enrollment Analysis 
Rates of unenrollment from the GS study were compared using Kaplan Meier curves 
generated with Graphpad Prism. Enrollment and unenrollment data came from GS Study 
archives. In the GS Study, unenrollment was required upon reaching T-cell counts of 200, 
or concurrent counts >300 cells/mL in the circulation or at the discretion of the patient or 
clinicians. Patients who left the study with high CD4 counts were excluded from the study, 
and only those with CD4 counts below 300 cells/mL and remained in the study for at least 
1,000 days were analyzed. Upon unenrollment patients were provided with treatment. 
Comparisons were made between infecting subtypes. A total of 282 (114 Ugandan and 168 
Zimbabwean) patients were included in this analysis. Curves were statistically compared 





Figure 3.2) CD4+ T-cell GEE calculated decline rates separated into A) the cohort subset 
compared to the previously published entire cohort analysis, B) total CD4+, memory 
(CD45R0+), and naive populations (CD45R0-) or C) separating the memory population into its 
constitutive central (CCR7+) and effector (CCR7-) memory parts. Infecting subtypes, A, C, or D, 






3.3.1 Analyses of CD4+ and CD8+ T-cell subsets during HIV-1 
disease 
As described in Chapter 2, we recruited 303 women following acute/early infection into 
the GS Study. Subsequent follow-up visits were scheduled monthly for the first six months, 
every three months for the first two years, and then every six months up to 9.5 years 
between 2001 and 2010. At the time, and based on the availability of antiretroviral drugs, 
all women were eligible for cART when CD4+ T cell counts fell below 200 per mL of 
blood or concurrent counts below 300 per mL.  In contrast, the Joint Clinical Research 
Centre in Kampala, Uganda has a test-and-treat policy where cART is provided to an HIV 
infected individual regardless of the CD4+ T cell count. Thus, this study provides one of 
the most comprehensive analyses of the natural history of HIV disease in those infected 
with non-subtype B HIV-1. Sample collections during the cohort study were also extensive 
with blood, vaginal, and cervical samples collected every 3 months. PBMCs were purified 
from blood every 3 months. 
In this study we compared rates of T-cell loss between Group M subsets to identify the role 
of memory T-cell depletion in HIV disease progression.  Using cryopreserved, purified 
PBMCs, we stained the cells with either anti-CD4, CD45R0, and CCR7 antibodies (for 
CD4+ subsets) or anti-CD8, CD45R0, CD38 and HLA-DR antibodies (for CD8+ subsets). 
Flow assisted cell sorting (FACS) identified the percentages of T-cell subsets. CD4+ 
populations identified were CD4+/CCR7+/CD45R0- T-cells (naive), 
CD4+/CCR7+/CD45R0+ T-cells (central memory), and CD4+/CD45R0+/CCR7- (effector 
memory) as described in Figure 3.1A. CD8+ populations identified were CD8+/CD45R0- 





3.3.2 HIV Subtype impacts depletion of CD4+ and CD8+ 
populations 
We first compared the CD4+ T-cell declines between the subgroup samples (69 patients) 
relative to the total patient population (303 patients) over the course of infection (Figure 
3.2A). Generalized estimating equation models are considered the gold standard for 
longitudinal data analysis in order to account for covariance due to multiple measurements 
within a single patient over time. This model also corrects for varying numbers of 
observations per patient and allows for flexible error structures. Autoregressive error 
structures (AR-1) suggest that the correlation between two cell count measurements in a 
given patient is a function of the time between the visits, with reducing correlations over 
greater time. These relationships most accurately resemble the data and dynamics of the 
human immune system generally and were employed in all the analyses herein.  
The results reconfirm previous conclusions about differential disease progression between 
subtypes even with a limited number of patient samples available (Figure 3.2A). Subtype 
C infections showed a highly statistically significant reduction in the rate of all CD4+ T-
Cell loss, about 0.63 cells per week, relative to that of subtype A (p<0.0001, GEE), losing 
about 1.03 cells per week, both of which differ from subtype D, which loses about 1.22 
cells per week (all pairwise comparisons p<0.0001, GEE) (Figure 3.2B). Our analyses also 
found that while viral load correlates with the loss of CD4+ cells, these relationships do 
not differ between subtypes (Supplementary Figure 3.3). 
Pooled memory subsets, CD4+/CD45R0+ T-cells, also showed reductions in pathogenesis 
by subtype C relative to A and D (C vs. A, p<0.0001, GEE; C vs. D, p=0.019, GEE, Figure 
3.2B).  In other words, the decline in the memory CD45R0+ T-cells was slower when a 
patient was infected with subtype C.  Analyses of this cohort subset showed that the more 
rapid declines in memory CD45R0+ T-cells with HIV-1 A and D infections did not 
significantly differ from each other and does not suggest, based on the memory CD45R0+ 





population also displays a wide range of memory CD45R0+ T-cell losses during subtype 
C infection (+/- 0.75 cells per week) with some subtype C infected individuals having no 
decline of memory CD4+ T-cells during ~6.5 years of infection.  In contrast, all 118 
subtype A and D infections had a progressive loss in the memory CD4+ T-cell populations. 
The CD4+ naive population did not change in frequency over the course of infection 
regardless of infecting subtype (Figure 3.2A).  
To further interrogate the individual memory subsets, the central and effector memory 
populations were separated and compared directly by staining for CCR7 and CD45R0 
(Figure 3.2C). Statistically significant differences based on infecting subtype can be 
observed in the effector memory CD4+ T cells over the ~6.5 years of infection (C vs. A, 
p<0.0001, GEE; C vs. D, p=0.004, GEE, Figure 3.2C). Separating memory T-cells 
populations showed that central memory T-cell counts did not significantly decline during 
HIV infection (p=0.1271, Linear reg., Supplementary Figure 3.1) and there were also no 
significant differences related to the infecting HIV-1 subtype (Figure 3.2C).  
CD8+ T-cells, while not directly infected by HIV, have been shown to lose function and 
decline due to bystander effects during untreated HIV disease [34]. Our measurements of 
CD8+ T-cell populations are unable to show these losses of cells in subtype A and C 
infections, but the most pathogenic subtype, subtype D, shows consistent and significant 
CD8+ cell depletion of about 0.5 cells/week (Figure 3.3). These declines in subtype D 
CD8+ T-cell populations are visible in total cell measurements but are largely driven by 
the loss of memory cells, which only declined in subtype D infections. Numbers of naive 





Figure 3.3) CD8+ T-cell GEE calculated decline rates separated into memory (CD45R0+), 
and naive (CD45R0-) populations. Infecting subtype is listed below. P values calculated 







Figure 3.4) CD4+ and CD8+ memory T-cell dynamics (CD45R0+) for 27 patients with 
typical disease progression for infections by each subtype in women who participated in 






during 6.5 years of infection and regardless of the infecting subtype.  
Typical HIV disease depletion of CD4+ and CD8+ memory T-cells for patients infected 
with each Group M subtype are shown in Figure 3.4. These example patient measurements 
provide a better visualization of the steady linear depletion of these subsets, as well as the 
subtype D specific depletion of CD8+ memory T-cells. Patient subtype A infections largely 
resembled subtype D depletion of CD8+ memory T-cells. Subtype C infections remain 
largely steady over the course of infection, with clear proliferative events between visits 
that are not seen in the other Group M subtypes. All HIV infected patients experienced 
CD4+ memory T-cell depletion over the 6.5 years of monitoring. These cell losses appear 
consistent and steady in both subtype A and D infections, while subtype C, mirroring CD8+ 
memory T-cells, show greater stochasticity.  
The simultaneous expression of CD38 and HLA-DR was used a marker for the activated 
CD8+ T-cell population but did not identify subtype specific activation in naive or memory 
populations during HIV infection (Supplemental Figure 3.2). There was however a trend 
for higher CD8+ T-cell populations in the subtype C infected patients as compared to those 
infected with subtype A and D.  This trend was most apparent in the memory and activated 
CD8+ T-cell populations.  
As described above, subtype C infections led to apparent slower declines in the effector 
memory CD4+ T-cell population than did infections with subtypes A or D.  Indeed, the 
slower declines in the entire CD4+ T lymphocyte population suggest slower disease 
progression by subtype C, which may be attributable to both a reduced activation and 
transition of memory CD4+ T-cells to effector memory T-cells.  The effector memory T-
cells could die due to TCR initiated-programmed apoptosis, direct HIV cytopathogenicity, 
or HIV-related direct or bystander apoptosis. Importantly, viral load analyses on both the 
cohort subsets analyzed here, as well as the broader cohort, have not identified lower 
circulating virus concentrations during subtype C infections (p=0.219, ANOVA, 





Given the wide range in the CD4+ T-cells memory and CD8+ memory T-cell counts 
(CD45R0+) over the course of subtype C infections, we performed a correlative analysis 
between these two cell types to investigate differing relationships between these cell types 
during Group M subtype infections (Figure 3.4). Linear regressions by infecting subtype 
showed statistically significant correlations between the dynamics of the CD4 and CD8 
memory subsets (Linear regression, p=0.002). These correlations highlight the CD4+ T-
cell independent depletion of CD8+ T-cells during subtype D infections. Infections with 
subtype D are the only subtype to show a negative correlation between CD4+ and CD8+ 
memory T-cells (Figure 3.5). The depletion of CD8+ T-cells during subtype D disease has 
major implications for viral control but, without increased activation markers in CD8+ T-
cell populations, relies on a yet undiscovered mechanism. 
3.3.3 Rates of study unenrollment agree with other 
pathogenicity measurements 
Other studies on pathogenicity of HIV-1 Group M subtypes used the time to clinical AIDS 
as a measure of pathogenicity. We used unenrollment from the study as a proxy 
measurement for clinical AIDS since patients were unenrolled to receive treatment after 
concurrent CD4+ T-cell counts below 300 cells/mL in their circulation. Subtypes C and A 
were statistically indistinguishable (p=0.9451), while subtype D infected patients 
unenrolled earlier than subtype C (p=0.0444) and nearly differed from subtype A 







Figure 3.5) Correlations between CD4+ memory T-cells and CD8+ memory T-cells 
(CD45R0+ populations) between Group M subtype infections. Observations made between 
100 days post infection and 2,100 days post infection. Comparisons between the slopes of 






Figure 3.6) Kaplan Meier analysis for patient enrollment by infecting subtype. Patients 
included in this analysis must have remained in the study for >1000 days and reached a 
CD4 count below 300 cells/mL. Subtype A median enrollment was 2,239 days, subtype C 






In both HIV and SIV infections, many of the immunodeficiency symptoms and 
opportunistic infections are directly related to the loss of effector memory cells and the 
ability of these cells to rapidly respond to non-HIV recall antigens [35, 36]. Primate models 
and other investigations have shown that these cells are the first to become exhausted and 
undergo apoptosis. Here we show that effector memory cells are the primary CD4+ 
population to be depleted during untreated infection while naive and central memory CD4+ 
T-cells are nearly unimpacted, regardless of infecting subtype. 
The same pattern of differential pathogenicity of the most prevalent Group M subtypes in 
Africa is visible in T-cell memory (CD45R0+) population declines. Patients infected with 
subtype A and D viruses lose their CD4+ memory T-cells at about double the rate of 
subtype C. While subtype C viruses appear highly variable in their effects on memory T-
cells, the more pathogenic subtypes A and D specifically deplete CD4+ effector memory 
T-cells without depleting central memory or naive populations. These populations that 
remain unchanged over HIV-1 infection have been documented to be poorly infected, 
largely transcriptionally inactive, and non-dividing [24, 37]. While some depletion of these 
subsets may be expected due to bystander apoptosis, the lack of viral replication limits 
cytopathic effects, and the intrinsic apoptosis pathway. 
Infections with subtype C viruses induced varying CD8+ T-cell responses, over a much 
broader range than subtype A or D disease. This heterogeneous response to subtype C 
infection warrants future work to identify correlates of CD8+ T-cell proliferation. 
Published literature has detailed the prevalence of CTL epitopes in conserved regions of 
the subtype C accessory protein Nef, and the overwhelming preference of the CTL 
response to Nef epitopes in subtype C infections (97.5% of epitopes) [38, 39]. Recent 
subtype C reference strains from Brazil have also been described that harbor mutations in 





mutations may leave subtype C open to CTL clearance of infected cells and contribute to 
the differential pathogenesis observed here. 
Investigations into pathogenicity and fitness have routinely shown that subtype D is the 
most fit and pathogenic strain of HIV-1 Group M [41-43]. Using unenrollment from the 
GS study as an endpoint mimicking clinical AIDS, we compared enrollment by infecting 
subtype. While subtypes A and C did not differ in their rates of unenrollment, subtype D 
patients unenrolled at much greater rate. Results presented here also suggest that subtype 
D is unique in its depletion of CD8+ memory populations. In the absence of viral escape 
mutations, CD8+ T-cells are the primary mode of infected cell clearance, the breadth of 
which is linked to disease control [44]. However, it remains possible that the skew towards 
a memory phenotype (CD45R0+) CD8+ T-cell is a product of the disruption of natural 
lineage maturation in subtype C HIV infected patients [45].  
3.4.1 Preferential depletion of effector memory T-cells during 
HIV infection 
Simple models of T-cell homeostasis and activation show an accelerating depletion of the 
T-cell populations [31, 46]. As the immune system loses cells to activation-induced 
apoptosis, bystander apoptosis, and HIV cytopathic effects (CPEs), the bone marrow 
releases new uninfected naive target cells which, according to the second hypothesis, 
should migrate to inflammatory sites and become infected themselves. This “fuel to the 
fire” model would grow exponentially and deplete the immune system in months rather 
than years. However, patients rarely display this cell-loss dynamic and almost always have 
a slower, near linear progressive effector and memory effector T-cell depletion over the 
asymptomatic period of infection.  
One explanation draws from the finding that mature, peripheral T-lymphocytes are the 
primary source of new CD4+ T-cells in the periphery [47]. Specifically, mature T-cells 
transferred between HIV discordant twins were found to persist for months and expand 





and inflammation due to huge amounts of antigen produced from productively infected 
cells. The antigen naive HIV-specific T-cell population, in response to cognate antigen 
presentation, proliferate into transcriptionally active effector cells.  These cells are well 
documented to be preferentially infected by HIV, fueling viral replication, cytopathic 
effects and releasing more HIV antigens [22]. This cycle of activation seeds HIV-specific 
effector memory populations, long-lived cells capable of producing new virions for 
decades, further fueling post-activation apoptosis. It also results in the persistence of HIV 
infected cells in the periphery while gradually depleting the activated effector T-cell 
populations. This theory of T-cell depletion particularly highlights the role of inflammation 
and T-cell activation in their eventual apoptosis, while downplaying the impact of viral 
cytopathic effects. 
3.4.2 Implications 
Replicative fitness, CD4+ effector memory T-cell depletion, and cellular entry efficiency 
strongly correlate in a cohort of HIV-1 infected women. Subtype C displayed the least 
efficient attachment affinities, entry rates, relative fitness scores, and caused a disease that 
progressed at about half the rate of subtype D infections. The consistent patterns across 
widely differing analyses lends credence to these conclusions. Maintenance of CTLs 
during subtype C disease, and their gradual depletion during subtype D disease, may be 
major drivers of pathogenesis differences.  
However, regardless of subtype, HIV infections remain incurable. To fully consider 
strategies to eradicate HIV in lieu of a cure, the field must better understand the diversity 
of diseases caused by this virus, whether current estimates of undiagnosed infections are 
accurate and how treatment must be prioritized to minimize future transmission. To target 
the latent reservoir of integrated HIV-1 provirus, it’s critical to understand the dynamics of 
the cell types that harbor it. Most importantly, these considerations must be made using the 






Supplementary Figure 3.1) Cohort subset CD4+ T-cell Central Memory 
(CD4+/CD45R0+/CCR7+) cell counts over the course of HIV-1 infection. Observations 
within AHI, <100 days post infection, were excluded. Linear regression comparison with 









Supplementary Figure 3.2) CD8+ T-cells trends in activation markers CD38 and HLA-
DR over the course of infection by HIV Group M subtypes. Gating strategy shown on the 







Supplementary Figure 3.3) Cohort subset viral loads for all visits post AHI, <100 days 
post infection. Lines and dots denote Group M subtype, green = D, red = C, blue = A. 
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Chapter 4  
Discussion 
4.1 Viral Fitness, Disease Progression, and CD4 Binding 
Affinity 
This dissertation conclusively supports the link between replicative fitness and disease 
progression in HIV-1 Group M subtypes A, C, and D from a cohort of women in Uganda 
and Zimbabwe. Patterns of T-cell depletion strongly correlate with patterns of replicative 
fitness in activated PBMCs, such that subtype D is fitter and more pathogenic than 
subtype A, both of which are greater than subtype C (Figures 2.2 & 2.4). The patterns of 
cell depletion extend to memory subsets of CD4+ T-cells, but not naive or central 
memory T-cells (Figure 3.2). These data substantiate the notion that effector cells, and 
particularly effector memory cells, are the most depleted populations during untreated 
HIV disease. Chronic inflammation and immune activation drive the expansion and 
subsequent apoptosis of effector T-cells in the periphery, generate more infectible targets, 
release HIV antigens, and signal bystander apoptosis [1-4]. 
The size of the cytotoxic T-lymphocyte (CTL) population that target HIV-1 are 
associated with disease control and limiting viremia [5]. Analyses of CD8+ memory T-
cell population dynamics in the GS cohort demonstrate that only subtype D causes a 
statistically significant reduction in the number of circulating cells, while naive and 
activated subsets remained unchanged (Figure 3.3). These results demonstrate a possible 
mechanism of the rapid disease progression associated with subtype D infections, due to 
a depleted CTL response. This CD8+ cell depletion in subtype D infections appears to 
begin early in infection and does not correlate with losses of CD4+ T-cells or CD4+ 
memory T-cell subsets. Subtype C infections displayed a particularly wide range of effect 
on CD8+ T-cell counts, suggesting in some participants that CTLs proliferate even during 
active infection. This data may clarify why subtype C disease progresses so slowly 
relative to other Group M subtypes and warrants additional exploration. Studies 
attempting to predict CTL epitopes in subtype C viruses highlight the flaws in studying 
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only subtype B infections, thus the unique immune pressure on HIV subtype C by CTLs 
remains to be explored [6]. 
Links between fitness and pathogenesis have been previously suggested, however few 
studies have adequately addressed such a question [7-9]. In the analyses presented herein, 
we addressed many of the failings of previous studies through extensive medical 
surveying, PCR and seroconversion tests to closely estimate time of infection and 
accounted for host diversity more effectively than prior investigations. Finally, despite 
extensive analyses we did not find an impact of viral load, diet, environment, host 
genotype, sexual habits, country of origin, or hormonal birth control use that better 
explains the differences associated with HIV-1 Group M subtype. HIV disease, as with 
all human disease, is a complex system with many factors determining immune cell 
apoptosis and depletion. These analyses required very large numbers of observations in a 
large cohort to reach statistical significance while controlling for the other measurable 
factors known to impact pathogenesis.  
Previous work from our laboratory utilized diverse chimeric viruses to map the primary 
drivers of viral suppression in lieu of treatment. That study identified the Env 
glycoprotein, the viral protein responsible for virion attachment and cellular entry, to be 
the largest single contributor to elite viral suppression between HIV-1 clones [10]. Data 
presented here, using viruses from the GS Study cohort, also strongly implicated a role of 
viral attachment, entry, and fusion in CD4+ T-cells to account for fitness differences and, 
in turn, differences in virulence. The rate of cell-cell fusion, as a corollary to syncytia 
formation in the lymph nodes, showed statistically significant rate increases in subtypes 
A and D relative to subtype C (Figure 2.5b&c). These syncytia are a major marker of 
advanced HIV disease, disrupting lymph node architecture and interrupting immune 
system function. We also found that these rate changes extend to a viral particle entry 
model, to cover all modes of cell infection (Figure 2.5d&e). These rates of fusion and 
viral particle entry are likely driven by CD4 binding affinity differences (Figure 3.4). 
The differences between HIV-1 subtypes presented in this work are consistent with the 
patterns reported by our group and others [8, 11-17]. Investigations into Gag-Protease, 
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replicative fitness, disease progression, susceptibility to fitness-reducing mutations, viral 
entry rates, CD4 affinity, and proviral decay all identified subtype C as the least and 
subtype D as the most effective or fit subtype of those compared [8, 11-13, 15-25], each 
of which may be contributors to fitness differences between subtypes. It must be 
hypothesized that the combined reductions in fitness in subtype C might be adaptive.  
4.2 Subtype C Epidemic spread 
Over the past four decades HIV-1 has spread around the world. However, this spread has 
not been equally distributed between the Group M subtypes. Subtype C expanded the 
most and is currently the most prevalent in the world (55% of HIV-1 infections) [21, 24], 
with little research focusing on identifying why. The work presented here has identified 
significant reductions in pathogenicity in subtype C that may have driven this expansion 
[11, 12, 26, 27]. Mathematical models that estimate the effects of prolonged 
asymptomatic disease have shown strong positive correlations with disease spread [28, 
29]. It is worth noting that these models typically use data from more rapid disease 
outbreaks like Influenza A or SARS and may not accurately predict future HIV 
transmissions.  
South Africa has the highest incidence of HIV infections in Africa, 18.8% of adults 15-
49, while containing the highest prevalence of subtype C HIV in the world, 95%. The 
prevalence of subtype C infections in Brazil has also increased in the last decade while 
other subtypes plateaued [21, 24, 30]. But these findings remain limited due to the small 
number of appropriate populations, limited funding, and limitations of ethical human 
research. 
Past work from our laboratory suggest that these fitness differences between subtypes are 
consistent between regions [21, 22], but further analyses are required to demonstrate 
consistent patterns from other continents. Work from others has demonstrated the rapid 
disease progression of subtype D in Kenya, Rwanda, South Africa, Uganda, and Zambia 
[17, 31, 32]. The patterns of fitness in other regions appear to be strong indicators of 
pathogenesis as well. However, future work should continue to examine HIV-1 subtypes 
A, C, and D fitness and disease progression outside of Eastern and Southern Africa. 
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Ideally, future metanalyses of archived monitoring data from untreated HIV+ patients 
from around the world could assemble a much broader database than any single study. 
The results from the GS cohort suggest that human genotype has a significant impact on 
basal CD4+ T-cell counts but when accounted for, no other patient background 
measurements were necessary to identify subtype differences in pathogenesis. 
Understandably, the managers of trial data will be reluctant to share their patient records, 
and these analyses are unlikely to come to fruition, but are likely one of the few 
remaining avenues to investigate untreated HIV disease progression.  
It is also possible that the predominance of subtype C has been fueled by founder effects 
alone, since most HIV epidemics are established by a relatively small number of infected 
people with limited viral diversity [33]. Subtype B is documented to be one of the most 
pathogenic forms of HIV-1, and expanded into North America, Europe, the Caribbean, 
South America and Australia. These epidemics provide contradictory evidence to the 
hypothesis that fitness reductions spread HIV. Unfortunately, it is difficult to compare 
HIV transmission patterns between eras and populations. The difference made by 
HAART cannot be discounted and the overall decline of HIV transmissions may provide 
different selection pressures on the virus than was present in the 1960s and 70s.  
4.3 GS Study Cohort 
Research of human pathogens requires innovative research strategies and extreme care to 
maintain ethical research practices. In the design of the GS Study, from which the disease 
progression data was mined, it was extremely important to the study directors to provide 
as many resources to the participants as possible. While not required for ethics approval, 
counselling, frequent medical examinations and treatment upon unenrollment were 
provided to all participants. This was the first study of its kind to provide treatment to 
participants after enrollment, thus the study coordinators could state that the research and 
use of its data were navigated in the most ethical manner available. Despite this, later 
studies, like the 2015 Strategic Timing of Antiretroviral Treatment (START) study, 
found that delaying HIV treatment in the infected had severe consequences on long-term 
survival and disease management, even when these participants maintained CD4+ T-cell 
counts above 500 cells/mL [34]. Following these results, the WHO established new rules 
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about the ethical research of HIV+ populations that require treatment to be provided upon 
HIV diagnosis. These rules would make repeating the GS study, or any study for that 
matter, with similar approaches, impossible. Since these data are irreplaceable and 
unrepeatable, it is critical to maximize what we can learn from it. 
The GS study is also unique in its location and participants. Few human populations are 
as well suited to this study design as the enrolled Ugandan and Zimbabwean women. The 
human genetic diversity in the region is so vast as to mimic a much broader study area. 
This allowed for an economically efficient study design while also controlling for human 
genotype, a criterion not assessed in previous investigations. Genetic diversity and other 
covariates between the Ugandan and Zimbabwean populations did impact our analyses, 
primarily in the baseline CD4+ T-cell counts, prior to infection. Zimbabwean women 
naturally had lower CD4+ T-cell counts, which were suggested to play a significant role 
in how their diseases progressed. During the analysis we worked to address these 
concerns, both by including baseline T-cell counts in our model and by measuring CD4+ 
cell loss as a percentage of the participants starting cell count. Each of these strategies did 
little to change the results of the analysis, and only served to add variability and reduce 
overall model fit scores.  
Finally, the GS study data identified the date of HIV infection in a more analytically 
appropriate manner. Rather than enrolling HIV+ populations, the GS study enrolled 
participants from the HC-HIV study upon early PCR or seroconversion test. These 
diagnoses were then confirmed via PCR and a best estimate at the date of infection was 
calculated. This differs dramatically from other studies which estimate HIV infection date 
by viral load retrograde extrapolation [35, 36]. These errors in enrollment strategy 
typically overestimate the time since infection in participants with higher viral loads and 
more rapid disease progression, effectively dampening differences between participants.  
4.4 Future Directions 
Work is ongoing to explore the results presented herein. Varying rates of entry, cell-cell 
fusion and affinities for CD4 can be explained either through variation of viral surface 
Env expression or mutations that confer greater binding affinity and kinetic rate. HIV-1 
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subtypes that have low Env density on the viral surface would slow the receptor-ligand 
interaction rate and could account for the whole-virus affinity for CD4. The competitive 
ELISA presented in Chapter 2 measured CD4 affinity by an entire viral particle and not 
purified Env protein (Figure 2.6). Future work could also explore the per-Env trimer 
affinity differences for CD4 and would be worth pursuing regardless of the results of Env 
quantification experiments. Preliminary analyses to quantify the number of Env trimers 
per viral particle have failed to find differences in Env density. However, the fluorescent 
western blot protocol used has a relatively high limit of detection for the picogram 
quantities of Env we are trying to quantify. Transition to a chemiluminescent assay using 
antibodies conjugated to horseradish peroxidase (HRP) to amplify the band signal [37].  
Overall, these studies are especially difficult due to the variability between the HIV 
subtypes being measured. DNA sequence homology between subtypes A, C and D is 
about 85% with the greatest differences found in the env gene sequence. The impact on 
the binding strength of many monoclonal antibodies with epitopes in HIV Env has been 
documented and varies depending on subtype [38]. The monoclonal antibody B13 binds 
to the CD4 binding site (CD4bs) and is the most consistent antibody when binding 
diverse HIV strains [10, 39, 40]. Unfortunately, this antibody requires high titers for 
efficient binding and the linear epitope requires significant denaturing steps before 
blotting. This relatively poor interaction highlights the necessity of signal amplification 
through chemiluminescence. 
Expression differences of HIV-1 Env between subtypes would raise future questions 
about the subtype specific mechanisms at work. Both degradation in an endocytic 
compartment following reinternalization and weakened Gag-Env interactions during viral 
assembly and budding have been suggested [41]. Protocols developed in our laboratory 
for surface plasmon resonance (SPR) experiments would be able to measure both Env-
CD4 and Env-Gag interactions per trimer to clarify these binding results. Sample 
preparation would need to be highly purified to detect signal differences, likely requiring 
purified protein of different subtypes to be ordered from the NIH AIDS Reagent 
repository. These experiments could explore CD4 affinity for all available viruses from 
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around the world to see if the differences found in Uganda and Zimbabwe are 
maintained. 
A flow cytometry panel utilizing HIV entry sensitive dye and fluorescent antibodies 
differentiating lymphocyte populations is also being developed. This assay, when fully 
developed, could measure viral entry by cell type. Viruses used in these experiments 
contain dsRed2 sequences between the env and nef genes to quantify productive infection 
as well [42]. Long-term infection assays could use markers of pyroptosis (activated 
caspase 1) and apoptosis (activated caspase 9 or caspase 3) to clarify the mode of cell 
death, measured between HIV-1 subtypes and across all CD4 and CD8 T-cell subsets. 
Finally, the in vitro assays presented in this dissertation were developed to move into 
activated PBMC cultures from uninfected participants to explore differential virus entry, 
fusion and CD4 binding in the T-cell memory populations. Implementation and 
troubleshooting of these assays were beyond the scope of this work but is progressing to 
clarify the mode of cell death in these memory lymphocytes. The typical forms of T-cell 
death during HIV infection are bystander apoptosis, HIV cytopathic effects and post-TCR 
stimulation apoptosis. The first two of these modes have cannot be addressed by data 
presented in this thesis and are hotly debated in the field. The final, the role of TCR 
stimulation and immune activation, has been a focus of this research, however conclusive 
evidence of immune stimulation-based T-cell contraction is elusive.  
The engagement of the viral particle with the CD4 receptor, which we demonstrate here 
is heavily influenced by HIV subtype, may serve to “prime” these cells for future 
activation and expansion. Assays allowing HIV attachment but preventing cell entry 
show a significant increase in future activation levels in diverse T-cell populations. 
Future work will also explore whether the CD4 binding strength of the viruses 
themselves functions to modulate this chronic activation observed in HIV disease. While 
evidence in this dissertation is simply correlative, that subtype C has both a reduced CD4 
binding strength as well as a slower pathogenesis, future studies will investigate subtype 




The transcriptionally latent viral reservoir remains the final challenge in curing HIV [43, 
44]. “Shock and kill” strategies seeking to reactivate and destroy this pool of integrated 
provirus are in development. New data from a Rakai, Uganda cohort of primarily 
infections by Group M subtypes A and D, revealed that North Americans, infected with 
subtype B viruses, typically have larger pools of latent provirus than participants in the 
African cohort [45]. The relative size of the subtype C latent proviral pool remains to be 
quantified. This result strongly suggests a role for viral diversity in the size of the latent 
reservoir, with many future questions to be addressed.  
The impact of HIV diversity on latency may provide targets for cure strategies that push 
the integrated HIV provirus so deep into a latent state that it is unable to reactivate. These 
strategies, catchily termed “Block and Lock” therapies, are attempting to identify host 
factors to promote histone translocation, methylation and deacetylation near the 
integrated viral promoter to prevent future reactivation [46]. If Group M subtypes have 
naturally evolved ways for the virus to promote greater integration and latency, then this 
may become a viable therapeutic to limit viral rebound after ART cessation and lower the 
bar for “Shock and Kill” effectiveness. 
4.5.2 HIV Cure 
Cure strategies, elevated by the results of the RV144 Thai Trial vaccine, have begun to 
focus on non-neutralizing IgG antibodies due to their negative correlations with infection 
[47]. These antibodies are unable to neutralize the virus directly, but instead capture the 
virus in aggregates. Viruses bound by these antibodies cannot infect new cells and are 
instead phagocytosed [48]. Critically, these antibodies do not bind infected cells and 
promote antibody-dependent cellular cytotoxicity, instead relying on other forms of 
infected cell clearance. The data presented herein suggest that a vaccine that successfully 
stimulates this subclass of IgG antibodies may struggle to control advanced subtype D 
disease due to the unique depletion of CD8+ T-cells (Figure 3.3). CD8+ T-cells, or 
cytotoxic T lymphocytes (CTLs) play a key role in destroying infected cells [3]. Potential 
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pitfalls like these highlight the importance of considering the broader HIV-1 Group M 
diversity while moving forward. Neutralizing antibody research has already reached this 
conclusion and future HIV vaccine trials based in South Africa will utilize subtype C Env 
proteins in their formulation [49, 50]. These upcoming trials are likely going to be the 
most impactful in the history of the field, due to the better understanding of HIV control 
from the RV144 trial and incorporation of the most prevalent subtype in the pandemic, 
subtype C, in the vaccine itself. 
While optimism abounds following RV144, it is still important to find methods to limit 
HIV transmission in case a vaccine doesn’t materialize. The WHO goal for 2020 is for all 
countries to achieve 90/90/90 targets: 90% of HIV+ individuals aware of their status, 
90% of those patients to be on treatment and 90% of patients on treatment to be fully 
virally suppressed [51]. These goals are made especially difficult when considering the 
data presented on subtype C disease progression [52]. Expanded time to reach clinical 
AIDS following infection with a subtype C HIV-1 virus primarily expands the 
asymptomatic phase of infection. Estimates of prevalence of HIV can be badly skewed 
given a disease progression that doubles the length of time patients remain asymptomatic 
[53]. Misjudging the prevalence of HIV may be an especially dangerous mistake as 
subtype C moves into regions with huge populations, like India, China and southeast 
Asia. The delay in apparent symptoms of disease, when combined with local 
governments that are resistant to international interference, can allow epidemics to 
immerge quickly and overwhelm the limited resources to reach 90/90/90 targets. While 
these warnings may seem dire, the rapid expansion of the HIV epidemic in Russia and 
other former soviet states among intravenous drug using populations underscores this 
reality [54, 55]. Refusal to allow international organizations into Russia to accurately test 
HIV prevalence and incidence rates leaves this region and the whole world at risk.  
Research has historically, and continues to, focus on subtype B as a model of all HIV 
infections. Despite research highlighting major differences between subtypes, nearly 
every model strain of HIV-1 used in laboratories around the world is subtype B in origin 
[56]. Subtype specific traits impact how drug resistance develops, and in countries with 
limited available ART regimens, controlling HIV drug resistance will be the key driver in 
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reducing infection rates [9]. For example, China, a country with a burgeoning HIV 
epidemic, limits the import of foreign made HIV drugs [57]. These limits seek to bolster 
the Chinese pharmaceutical industry but prevent new therapeutics from reaching Chinese 
patients. The net effect is the prevailing use of older drug regimens that are prone to 
resistance. Viral resistance to newly developed ART drugs, like dolutegravir, an integrase 
inhibitor, are much less common relative to previous generations. Unfortunately, these 
drugs are currently blocked from import by the Chinese government. The broad genetic 
diversity in the infecting HIV strains in the country allows for recombination and 
possesses even more drug resistance capacity than a single HIV type would. Estimating 
future drug resistance on studies of subtype B alone woefully misjudge the problem at 
hand. 
4.5.3 HIV Policy 
HIV is not curable, regardless of subtype. However, that doesn’t imply that differences in 
pathogenicity between viral strains are not useful to inform policy and political decision 
about the epidemic. Renewed focus must be placed on diagnosing HIV+ patients, 
particularly in areas with circulating subtype C viruses, as HIV-related symptoms are 
likely not to appear until years after infection, perhaps reducing rates of diagnosis. Efforts 
must be made to place every diagnosed patient onto treatment as soon as possible, per the 
recommendations of the START study and WHO research guidelines. However, given 
the limited funding available, the aggressiveness of subtype D infections may aid in 
triaging patients of Sub-Saharan Africa. Economic retractions have pushed the 
President’s Emergency Plan for AIDS Relief (PEPFAR), the largest single contributor to 
HAART in Africa, to decline in recent years, limiting the availability of life-saving drugs 
[58]. In the face of impossible choices, informed policy is the last, best option. 
4.6 Concluding Remarks 
Work by generations of HIV researchers have pushed back against the pandemic, 
developing effective therapies and multinational eradication strategies. The number of 
new infections drops each year as those with the disease can live longer and healthier 
lives. While HIV is no longer the global menace it once was, it remains fundamentally 
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important to understand how the different forms of the disease manifest. In order to 
understand the details of HIV disease, explorations of the immune cells depleted may 
provide clarity in a search for a vaccine or future treatment. Finally, illustrating the 
differences between diseases caused by the North American forms of the virus and those 
found in Africa may prompt future research efforts to identify mechanisms and impacts 
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Sharing of equipment used for the preparation of a 
controlled-release oral opiate for injection is associated with 
HIV transmission 
5.1 Preface 
During my graduate research I was lucky to collaborate with multiple institutions and 
groups of researchers on many HIV-focused projects. Fortunately, I had the greatest 
involvement in a collaboration with the London Health Science Center, University 
Hospital, and St. Joseph’s Hospital. The city of London, Ontario was experiencing an HIV 
outbreak linked to injection drug use and clinicians were looking for basic science 
collaborators to experimentally examine the feasibility of their hypotheses. I’ve included 
the subsequent manuscript from this collaboration because of its importance in my graduate 
work despite its incongruity with the HIV diversity project presented above. 
5.2 Abstract 
In London, Canada, an outbreak of HIV among people who inject drugs (PWID) occurred 
despite widespread distribution of sterile needles, syringes and IDPE. Hydromorphone 
controlled-release capsules (HCR) are the local opioid of choice (followed by immediate-
release hydromorphone) and is associated with frequent reuse and sharing of IDPE. Sharing 
of needles/syringes is a known and well documented mechanism for transmission of HIV 
amongst persons who inject drugs (PWID).  Injection drug preparation equipment (IDPE; 
i.e., cookers, filters) are more often shared than needles/syringes, but the risk of HIV via 
this mode of transmission is unknown. The objective of this study was to determine 
whether the practice of sharing injection drug preparation equipment (IDPE) to inject 
controlled-release opiates is associated with HIV transmission; and to examine the 




A case control study of HIV infected and HIV uninfected PWID cases was conducted using 
a questionnaire to examine behaviors associated with injection drug use. The primary 
exposure of interest was IDPE sharing over the last three months. To assess motivation to 
share/reuse IDPE, residual opioid left in the IDPE after aspiration with a needle/syringe 
was measured in conditions replicating PWID practices using liquid chromatography–
tandem mass spectrometry. To assess conditions favouring HIV transmission, HIV was 
added to IDPE in the presence or absence of opioid. HIV viral persistence was then 
measured in IDPE by HIV reverse transcriptase activity and infectivity of indicator Tzm-
bl cells. All experiments were done with HCR versus immediate-release hydromorphone 
and a control.  
Sharing IDPE (without sharing needles/syringes) was associated with HIV infection 
[aOR=22.1; p<0.001]. IDPE reuse was almost universal among HCR users [31/31 (100%) 
HIV+ and 62/66 (94%) HIV–]. Patient report of barriers and negative beliefs regarding 
heating HCR in the IDPE was also associated with HIV infection (p<0.05). Approximately 
45% of HCR remained in the IDPE following initial injection, with no change after heating, 
whereas only 16% of immediate-release hydromorphone was retained. HIV reverse 
transcriptase activity and infectivity were preserved in IDPE in the presence of HCR, but 
not in the presence of immediate-release hydromorphone. Heating the IDPE rapidly 
inactivated HIV despite the presence of residual HCR. 
IDPE sharing is associated with HIV infection. Hydromorphone controlled-release 
preparation leaves a significant drug residue in IDPE which encourages IDPE reuse and 
sharing among PWID.  HCR excipients preserve HIV viability which could potentiate HIV 
transmission in this population. Heating IDPE prior to drug aspiration may be an effective 
harm reduction strategy. 
5.3 Introduction 
Injection of prescription opioids has reached epidemic levels, resulting in an almost 
fourfold rise in hospital admissions in the United States between 2004-2014 [1]. This 
epidemic has also been associated with several large outbreaks of HIV [2,3] infection 
among people who inject drugs (PWID), including one in London, Ontario that resulted in 
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the declaration of a Public Health emergency (June 14, 2016) (Figure 1) [4]. The control 
of these outbreaks generally depends on a multi-pronged approach of needle distribution, 
opiate substitution therapy, and provision of antiretroviral therapy. Our outbreak was 
unusual as it occurred despite London already having at baseline the highest distribution 
of sterile needles and syringes per capita in Canada, and an opiate substitution therapy 
prescription rate in the top quartile for Ontario [5]. As well, London has a government-
funded, multidisciplinary HIV care program with access to funded HIV antiretroviral 
therapy. The reason for this outbreak despite the excellent pre-existing control programs 
was the subject of this investigation.   
A study of injection drug users in London identified hydromorphone controlled-release 
(HCR) capsules (Hydromorph Contin® [marketed as Palladone SR® in Europe], Purdue 
Pharma, Stamford CT, and marketed as Jurnista® in Australia, Janssen-Cilag Pty Ltd, High 
Wycombe, UK.) as the preferred opioid for illicit use.6 The majority of PWID (79%) 
reported HCR use in the past six months [6]. In addition, prescription rates of HCR capsules 
are unusually high in London compared to other regions in Ontario, which may indicate 
widespread availability of the drug for illicit use [5]. 
HCR capsules have a low solubility in water, and thus preparation of the drug for injection 
requires numerous steps (Figure 2) [7]. First, the time released beads must be removed 
from the capsule and crushed, then mixed with water in a cooker to create a slurry, and 
then drawn into a syringe through a cotton filter to remove visible particulate matter (Figure 
2) [7]. The filters, cookers and water are referred to as the injection drug preparation 
equipment (IDPE). The large dose of hydromorphone in the controlled-release formulation 
and the need to dissolve the capsule in a large volume of water increases the likelihood that 
the residual drug will be shared between users [7]. In addition, patients report large 
amounts of non-solubilized drug are retained in the filter and cooker after the first use, 
thereby encouraging the reuse and/or sharing of used IDPE [7,8]. Reuse of IDPE is done 
by adding water to the previously used cooker with residual drug still inside, placing a 
needle into the previously used filter and aspirating the residual drug (“doing another 




Sharing of needles/syringes amongst persons who inject drugs has been well established as 
a means of HIV transmission [9]. Thus, distribution of sterile needles/syringes has been a 
major focus of HIV prevention programs. However, sharing of IDPE is more common than 
sharing of needles/syringes [10–14].  In some centers, sharing of IDPE has been identified 
as the primary risk factor for Hepatitis C (HCV) transmission [10,15–17]. The incentives 
for sharing IDPE despite the existence of free IDPE distribution programs, and the impact 
of IDPE sharing on HIV transmission, have not been extensively studied. We propose that 
IDPE may initially become contaminated with HIV via a used needle from a PWID who 
reuses their own needle [18,19] and then HIV is transmitted when the IDPE is shared with 
a second user placing their own needle into the used filter/cooker to aspirate another 
“wash”. We further hypothesized that heating the contaminated IDPE prior to each use 
could inactivate HIV and help prevent transmission. 
The objectives of this study were to clarify the following: (1) whether sharing IDPE is 
associated with HIV infection, (2) the amount of residual hydromorphone in IDPE after 
the first injection [and thus the incentive for reuse or sharing of IDPE] and the effects of 
heating of the IDPE on the amount of hydromorphone available for injection, (3) the 
persistence of HIV in IDPE and the efficacy of heating to inactivate HIV to prevent 
transmission.  
5.4 Methods 
5.4.1 Setting  
The HIV outbreak in London, Ontario, was confirmed by comparing new diagnoses 
provided by the local Public Health Unit to regional and provincial figures. Cases were 
referred to as incident infections if no previous positive result for HIV serology or HIV 
viral load testing was available in the provincial database. Sociodemographic 
characteristics and risk factors for incident HIV cases were determined by reporting on the 




5.4.2 Association Between Sharing IDPE and HIV Infection 
A case-control study of HIV-infected (HIV+) and HIV-uninfected (HIV-) injection drug 
users was conducted to examine whether sharing IDPE is associated with HIV infection. 
The primary exposure of interest was IDPE sharing within the last 3 months. Inclusion 
criteria were age >17 years, residence in London-Middlesex county, Canada, and reported 
injection drug use within the last three months. A total of 127 participants were recruited 
from two sites: A) consecutive patients admitted to one of two local hospitals with a 
diagnosis of injection drug use associated endocarditis (as these were patients with high 
risk injection practices) and B) from a local needle exchange (where sterile 
needles/syringes/cookers/filters and sterile water were distributed). Recruitment occurred 
between August 11, 2016 and June 7, 2017. Routine HIV testing was performed using rapid 
diagnostic tests at the safe injection site and fourth generation testing at the hospital sites. 
Participants completed a detailed questionnaire regarding injection behaviors. The study 
was approved by the Research Ethics Board, Western University. Written informed consent 
was obtained from all participants.  
5.4.3 Power Calculation  
Based on a previous study that found a 40% prevalence of sharing IDPE amongst those 
injecting hydromorphone controlled-release [8], we estimated an exposure prevalence of 
20% in controls and 50% in cases, corresponding to an odds ratio of 4.0. A minimum of 
33 cases and 66 controls were needed to detect this association between sharing IDPE and 
HIV status, with 80% power, a 2-tailed alpha of 5%, and the continuity correction [20]. 
Final recruitment was 35 cases (HIV+) and 84 controls (HIV-).     
Analyses were conducted using SAS 9.4 (SAS Institute Inc. Cary, NC, USA). 
Sociodemographic characteristics and reported sharing behaviors between cases and 
controls were compared using logistic regressions. Chi-square tests were used to compare 
other categorical variables such as multiple washes of IDPE, and attitudes and beliefs about 
heating. Multivariable logistic regressions were conducted for the primary exposure of 
interest: IDPE sharing. If the addition of any sociodemographic variable demonstrated a 
confounding influence (>10% change), or interaction with, the IDPE sharing parameter 
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estimate, or if it was a significant independent predictor itself, it was retained in the 
multivariable models. Variables that met these criteria included: employment, housing, 
LGBTQ, and MSM; only housing and MSM were retained in the multivariable model as a 
result of multicollinearity with employment and LGBTQ variables, respectively. Two-
tailed tests were employed, and the level of significance was set to 0.05. 
5.4.4 Residual Hydromorphone in IDPE & Effects of Heating on 
the Amount of Hydromorphone Injected 
All experiments were performed with unused needles/syringes and IDPE equipment 
(sterile water, cookers, filters) (SterifiltTM Apothicom, Paris, Fr) that were distributed as part 
of the provincial harm reduction program, and thus commonly used by local PWIDs. To 
quantify the amount of residual drug present in the cooker and filter after an initial 
injection, we replicated the technique of crushing the drug, placing it in a cooker, dissolving 
it in water, and aspirating the solution through a filter (Figure 2). We developed this 
technique in consultation with local PWIDs. We performed this experiment with 
hydromorphone controlled-release capsule (24 mg) (Purdue Pharma, Stamford, CT) 
and immediate-release hydromorphone tablet (8 mg) (Pharmascience Inc., Montreal, PQ) 
as they are the doses and preparations most commonly injected locally.  Hydromorphone 
concentrations were measured using liquid chromatography–tandem mass spectrometry 
(LC-MS/MS). The effect of heating on drug stability was examined by heating the 




Figure 5.1) Incidence and count of HIV infection in Middlesex-London and Ontario, 
2005-2017. The Ontario (ON) and Middlesex-London (ML) HIV rates (per 100,000) are 
shown in the red and green lines respectively. Middlesex-London HIV incident cases per 
year are shown in the green bars. * denotes significantly higher (p<0.05) incidence of HIV 




5.4.5 HIV Persistence in IDPE & Effects of Heating on HIV  
All experiments with replication competent HIV-1 were performed in a BSL2+ facility 
with appropriate safety and waste protocols. Hydromorphone controlled-release capsules 
and immediate-release hydromorphone tablets were prepared as above (schematic in 
Figure 1). Two controls were used for each experiment 1) 250 mg of the excipient 
microcrystalline cellulose (Sigma) was added to the cookers, or 2) the cookers remained 
empty. Microcrystalline cellulose is a common filler/stabilizer in controlled-release drug 
formulations including hydromorphone controlled-release. HIV-1 (CXCR4 tropic 
genotype #1389) at titer of 1*108 infectious particles per mL was diluted 1:5 in sterile water 
(Sigma) and 1.5 mL was added to each cooker.  
Following a five-minute, room temperature incubation, the water was aspirated through the 
filter with a syringe (sans needle per containment lab requirements). This injectate 
preparation protocol was repeated with serial washes at 1 hour, 4 hours, 24 hours, 48 hours, 
and 72 hours for a total of six preparations for each filter. Filters were collected after the 
final aspiration. Insoluble residual material from the hydromorphone controlled-release 
and microcrystalline cellulose cookers was collected after the 24, 48, and 72-hour time 
points (50 mg per time point). To measure HIV viral persistence, injectates were split into 
aliquots for HIV reverse transcriptase and infectivity assays using Tzm-bl cells. Protocols 
for these assays have been previously published [21].  
To assess the effects of heating on HIV persistence, cookers were heated with an ethanol 
flame until bubbles formed around the edge of the cooker. All laboratory experiments were 
performed in triplicate with standard error bars displayed. Heating experiments were 
performed according to BSL2+ safety protocols in a biosafety cabinet with an ethanol 
flame. Cookers were heated until bubbles formed around the edge of the cooker.  
Prior to 2012, the filters distributed by harm reduction sites in Ontario were originally 
intended for the dental industry. These filters are made of rolled, less dense cotton with no 
chemical binding agents, additives, or whiteners (Maxill 53190). The filters distributed 
since 2012 are made of pressed cotton and coated with methylethyl-cellulose (Apothicom, 
France). Filters were cut to normalize by weight between generations.  
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Figure 5.2) Method for preparing Hydromorphone controlled-release for injection. 1) Open hydromorphone controlled-release 
capsule and empty time release beads into a pill crusher to crush the beads. Crush beads into a fine dust. Many individuals opt to use 
the bottom of a disposable lighter or the tops of syringe plungers to crush the beads as opposed to a pill crusher. Empty the crushed 
beads into a cooker. 2) Place a cotton injection filter into the solution. 3) Add approximately 1.5mL of water to the cooker. Allow cooker 
to sit for 5 minutes at room temperature to dissolve the opioid. 4) Draw up the solution into a syringe and inject. 5) Individuals usually 
opt to perform multiple “washes” whereby further water is added to the residual drug in the cooker/filter and the used needle is 
reintroduced into the same filter. The individual will then draw the additional drug solution and re-inject. Multiple users may participate 
with “serial washes” using the same filter/cooker/crushed-drug complex and patients reusing their own needle/syringe into a common 
filter.
145 
   
5.4.6 Community Interventions 
Based upon the results of the above investigations a community education project was 
carried out starting on June 15, 2017. This involved peer mentors, injection equipment 
distribution staff and public health officials spreading a message to PWIDs to “cook your 
wash” ie heat the IDPE containing the drug and filter and water, with a cigarette lighter 
until bubbling prior to any injection of hydromorphone. Local mass media was also used 
to spread this message (see “London researchers may have pinpointed why rates of HIV, 
other diseases rising among drug users” in the London Free Press, October 27th, 2017). In 
October 2017, a program of health care navigators to enable HIV infected patients to attend 
their medical appointments was initiated. These staff were also involved in the education 
campaign.  
5.5 Results  
HIV incidence in London rose above that in other regions of Ontario in 2015 and 2016 
(Figure 1) (p<0.05). The incidence remained high in early 2017 but fell in the latter half of 
2017 and was no longer significantly different from that of Ontario for 2017 as a whole.  
Data from 2016 suggested that the most frequently reported exposure category among new 
HIV cases in London was “injection drug use” (n=45/60; 75%), whereas <10% of new HIV 
cases occurred amongst persons who inject drugs in the same time period in the rest of 
Ontario. Mean age of new HIV cases was 37.6 years (SD=9.7). Sixty four percent were 
male.  
5.5.1 Association Between Sharing IDPE and HIV Infection 
One hundred and twenty-seven patients were recruited into the case control study. Eight 
participants were excluded due to unknown HIV status. The remainder were divided into 
cases (HIV infected; n=35) and controls (HIV uninfected; n=84). 
Cases (HIV+) and controls (HIV–) for this study were all persons who inject drugs, living 
in London, and were similar with regards to age, sex, housing status, race, employment, 
and recent endocarditis (Table 1). There was no difference in the proportion of inpatients 
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(recruited from the hospital site) and participants recruited at the safe-injection site, in the 
case and control groups.  
Unadjusted (Table 1) and adjusted (Table 2) models showed that HIV infection was 
strongly and consistently associated with sharing IDPE among persons who inject drugs. 
HIV infection was associated with men-who-have-sex-with-men status, although the 
association was weaker than sharing of IDPE. Sharing needles/syringes in the absence of 
IDPE sharing was not associated with HIV status. Removing either MSM status or housing 
status from the regression model did not change the results.   
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Table 5.1) Characteristics of HIV infected and HIV uninfected Persons Who Inject 
Drugs 
 
 Case (HIV +) 
(n = 35) 
Control (HIV –) 
(n = 84) 
Odds Ratio (95% 
Confidence Interval) 
Injection Equipment Sharing1    
     None 14 (42%) 61 (73%) Reference 
     Only needles/syringes 4 (12%) 16 (19%) 1.09 (0.32, 3.76) 
     Only IDPE#  10 (30%) 3 (4%) 14.52 (3.53, 59.77)* 
     Both IDPE# and 
needles/syringes 
5 (15%) 3 (4%) 7.26 (1.55, 34.03) * 
Sociodemographic factors 
   
    Age 38.4 (10.2)^ 41.2 (10.5)^ 1.03 (0.99, 1.07) 
    Female 6 (17%) 21 (25%) 0.62 (0.23, 1.70) 
    MSM2 5 (18%) 2 (3%) 6.63 (1.20, 36.60) * 
    LGBTQ3 3 (12%) 7 (9%) 1.29 (0.61, 5.39) 
    Stable housing4 19 (54%) 34 (41%) 1.71 (0.77, 3.79) 
    Aboriginal 
(REF=Caucasian)5 
9 (26%) 17 (21%) 1.33 (0.53, 3.39) 
    Stable employment6 2 (6%) 5 (6%) 1.02 (0.19, 5.53) 
    Endocarditis 9 (25%) 14 (17%) 1.73 (0.67, 4.48) 
148 
   
Injection drug use 
   
    Hydromorphone 
controlled-release 
31 (89%) 66 (79%) 2.11 (0.66, 6.77) 
    Immediate-release 
hydromorphone 
20 (57%) 64 (76%) 0.42 (0.18, 0.96) * 
    Methamphetamine 27 (77%) 63 (75%) 1.13 (0.44, 2.85) 
* Highlights significant values 
# IDPE= Injection Drug Preparation Equipment 
^ Standard Deviation 
1 Sharing data available for 33 cases and 83 controls 
2 MSM (men who have sex with men) data available for 28 cases and 63 controls 
3 LGBTQ (lesbian, gay, bisexual, transgender and queer) data available for 26 cases and 76 controls 
4 Housing data available for 35 cases and 83 controls 
5 Race data available for 34 cases and 80 controls 
6 Employment data available for 33 cases and 84 controls 







   
 
Table 5.2) Associations of HIV status with injecting behavior and Risk Factor variables. 
Logistic Regression. 
 




   Both IDPE and needle/syringes 23.88 (2.36, 241.82) .007 
   Only IDPE 22.12 (4.51, 108.59) <.001 
   Only needle/syringes 0.91 (0.16, 5.37) 0.92 
MSM 11.34 (1.79, 71.69) 0.01 
Stable housing 1.83 (0.55, 6.10) 0.32 
Adjusted odds ratio (OR) and associated 95% confidence interval (CI) are presented 
IDPE: injection drug preparation equipment; MSM: men who have sex with men 
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5.5.2 Residual Hydromorphone in IDPE & Effects of Heating on 
the Amount of Hydromorphone Injected  
Forty-five percent of the total hydromorphone in the hydromorphone controlled-release 
capsule remained in the IDPE after the first aspiration (and thus was available for use in a 
subsequent “wash”), whereas only 16% remained in the IDPE when using immediate-
release hydromorphone tablets (Figure 3). Heating during the injection preparation did not 
significantly change the amount of hydromorphone controlled-release in the injectate or 
the amount recovered from the IDPE (Figure 3). The preparation boiled (reached bubbling) 
in less than 10 seconds when using a cigarette lighter.  
Patient behavior reflected the findings of high drug residual in hydromorphone controlled-
release preparations. The case control subjects reported performing multiple washes of 
used IDPE more frequently when using hydromorphone controlled-release than with other 
drugs. Multiple washes were reported when using hydromorphone controlled-release  
[93/97 (96%) (of whom 31/31 HIV+, and 62/66 controls)], in comparison to immediate-
release hydromorphone [41/84 (49%) (12/20 HIV+, and 29/64 controls); p<0.001] and 
crystal methamphetamine [19/92 (21%) (9/29 HIV+, and 10/63 controls); p<0.001] 




   
Figure 5.3) Relative amount of hydromorphone recovered in syringe (injectate 
sample) and injection drug preparation equipment (filter and residue samples) with 
and without heating with A) 24mg of hydromorphone controlled-release and B) 
Immediate-release hydromorphone 8mg. Error bars represent standard error. 
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5.5.3 HIV Persistence in IDPE & Effects of Heating on 
Persistence 
Simulating drug preparation habits with a known inoculum of HIV-1 (Figure 2) allowed 
us to quantify relative viral persistence in different IDPE environments (Figure 4). Tzm-bl 
cells are highly susceptible to HIV infection and were used to quantify viral infectivity in 
the injectate samples under conditions employed by PWIDs. When preparing HCR for 
injection, infectious HIV was recovered from the zero-, one-, and four-hour time points, 
representing washes one, two, and three of HIV-inoculated IDPE. Significantly less 
infectious HIV was recovered from HIV-inoculated IDPE used when preparing immediate-
release hydromorphone compared to hydromorphone controlled-release.   Infectious HIV 
recovery was intermediate from HIV-inoculated IDPE that contained microcrystalline 
cellulose as a control (Figure 4A). 
The limiting sensitivity of the Tzm-bl assay prevented us from measuring infectivity 
beyond four hours (third wash). Previous work has indicated that reverse transcriptase 
activity in HIV-1 is a strong predictor of virus infectivity and has greater 
sensitivity/specificity than other surrogate assays such as p24 ELISAs or viral RNA load 
[22]. In the presence of HCR, and to a lesser extent microcrystalline cellulose, HIV reverse 
transcriptase activity persisted in the filters for 72 hours after inoculation and six serial 
washes, whereas HIV was not detected in the same conditions when originally mixed with 








   
Figure 5.4) Infectious HIV 
persistence after addition to 
Injection Drug Preparation 
Equipment. 
A) Infectivity of HIV-1 in injectates 
as determined by Tzm-bl cell 
luciferase production. HIV-1 was 
spiked into cookers containing 
opioids and expedients to measure 
viral persistence. Serial washes with 
sterile water were collected 5 
minutes, 1 hour and 4 hours post 
addition of virus.  Maximal 
preservation of infectivity over time 
seen with Hydromorphone 
controlled-release across all 
measured timepoints. Error bars 
represent standard error. * 
significant at p<0.05 via two-way 
ANOVA with Tukey’s correction 
for multiple comparisons. B) HIV-1 
reverse transcriptase activity after 72 
hours in injectates (after 6 washes). 
Only hydromorphone controlled-
release and Microcrystalline 
Cellulose continued to show above-
background reverse transcriptase 
activity at this last timepoint. 
Dashed lines represent assay 
detection limits. Error bars represent 
standard error. * significant at 
p<0.05 via two-tailed t-tests. 
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Figure 5.5) Reduction in infectious HIV-1 (measured via Tzm-bl cell luciferase 
production) after 10 second heat treatment.  HIV-1 was added to cookers containing 
hydromorphone controlled-release 24mg and an Apothicom filter and washed with sterile 
water (Injectate Washes 1 & 2 were collected 5 minutes and 1 hour after HIV-1 addition 
respectively). Cookers were then heated above an ethanol flame for 10 seconds or left at 
room temperature. Persisting infectious HIV-1 was quantified via luciferase production 
from Tzm-bl cells. Dashed line represents assay detection limit. Error bars represent 







   
To identify the location of the HIV-1 reservoir in the IDPE, we measured reverse 
transcriptase activity in the insoluble drug material and filters independently, both 
“housed” in the cooker, after 72 hours.  Higher levels of reverse transcriptase activity (i.e. 
HIV) were observed in the filters in the presence of hydromorphone controlled-release 
compared to the other compounds (Supplemental Figure 1). Heating the cooker liquid with 
HCR or hydromorphone immediate-release to a boil reduced the residual HIV-1 titers 
(infectious or reverse transcriptase activity) by two logs, to the limits of detection (Figure 
5). 
5.6 Discussion 
5.6.1 Association Between Sharing IDPE and HIV Infection 
We demonstrate that sharing of IDPE among injection drug users was a strong risk factor 
for HIV infection. We cannot differentiate risk associated with specific drug preparation 
equipment (i.e., filters versus cookers, rinse water, or residual drug), as these items are 
almost always used and shared concurrently [17]. However, the significant amount of 
viable virus found within the filters at 72 hours suggests that inserting an unused needle 
into a shared filter could lead to infection (Supplemental Figure 1). We also found that 
sharing both IDPE and needles/syringes was associated with an increased risk of HIV 
transmission. However, this result was likely driven by sharing IDPE, as sharing 
needles/syringes alone was not a significant factor in HIV infection in our study, and the 
adjusted odds ratio (aOR) of sharing both IDPE and needles/syringes was similar to that of 
sharing IDPE alone. Sharing of needles and syringes has been shown to be a risk for HIV 
infection in other settings, however our study occurred in an area with an exceptionally 
large needle/syringe distribution program enabling assessment of the impact of IDPE 
sharing when needle/syringe sharing is relatively infrequent. In contrast to our study, a 
recent HIV outbreak in Indiana demonstrated a 90% rate of needle/syringe sharing amongst 
HIV+ patients and 66% amongst HIV negative controls during the outbreak. Our much 
lower rates of needle/syringe sharing allowed the impact of IDPE sharing to be detected. 
Therefore, as needle/syringe distribution programs are rolled out, interventions to prevent 
HIV transmission associated with IDPE sharing will become increasingly important to 
eliminate further HIV transmission. 
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As in previous studies [8,10,12–14] we found that sharing filters and other IDPE occurs 
often. This is likely because the risk of HIV transmission with IDPE is not 
recognized.  Participants who avoided needle/syringe sharing frequently reported IDPE 
sharing several times per day. Those who share needle/syringes likely do so very rarely, 
due to the known significant associated risk. Therefore, even if the risk of HIV infection 
associated with a single episode of needle/syringe sharing may be higher than that of a 
single episode of IDPE sharing, the high frequency of IDPE sharing contributes to a greater 
cumulative risk. We also suspect that due to awareness of the risks associated with 
needle/syringe sharing, individuals may only do so with partners whom they believe are 
sero-concordant. Due to a lack of awareness of the risk associated with IDPE sharing, we 
believe that individuals do not avoid this behavior, nor do they attempt to sero-sort with 
IDPE sharing. Further studies are necessary to confirm this hypothesis. 
5.6.2 Residual Hydromorphone in IDPE  
These results provide the first evidence that 45% of the contents of a hydromorphone 
controlled-release capsule remain in the IDPE after an initial use, thereby incentivizing the 
behavior of frequent reuse of the IDPE to access retained HCR. The local street value of a 
capsule of hydromorphone controlled-release is approximately $60 CAN ($45.60 US) and 
therefore, disposal of the remaining drug in the IDPE is very uncommon. This leads to 
IDPE being commonly shared and sold among persons who inject drugs, despite nearly 
exclusive use of fresh needles/syringes [7]. In contrast, the low quantity of residual 
immediate-release hydromorphone on the IDPE, due to its lower dose and the high 
solubility of immediate release opioids, provides less incentive to reuse the IDPE. Our 
study confirmed that reuse was indeed most common with hydromorphone controlled-
release and less common with hydromorphone immediate-release or crystal 
methamphetamine. 
5.6.3 HIV Persistence in IDPE 
It has previously been demonstrated that HIV RNA can be found in high titer in IDPE used 
by persons who inject drugs, although the specific drugs used and their relative abilities to 
preserve HIV were not described in these studies [18,19]. HIV survival has been found to 
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be reduced in the presence of heroin, but it is unclear whether this was related to the heating 
process required for home production or the many caustic chemicals added to produce the 
solution [23]. To our knowledge, this study is the first to assess HIV persistence in the 
presence of prescribed opioids that do not require heating or the addition of extra chemicals 
for solubility. We demonstrated prolonged HIV survival in IDPE used in the preparation 
of controlled-release opioid (up to 3 days) compared to that used for an immediate-release 
opioid preparation. The dual effect of a controlled-release opioid which not only increases 
HIV survival in IDPE but is also retained, thereby providing an incentive for sharing IDPE, 
appears to be synergistic in facilitating HIV transmission.  
HIV persistence may be related to excipients in the long-acting preparation, as persistence 
was not seen with hydromorphone immediate-release tablets. Specifically, excipients in 
hydromorphone controlled-release that are not in immediate-release hydromorphone 
include ethyl cellulose, hydroxypropyl methylcellulose, and microcrystalline cellulose. 
Addition of microcrystalline cellulose alone to the IDPE retained more viable HIV and for 
longer than IDPE used with water or IDPE used with immediate-release hydromorphone. 
We were unable to obtain pure hydromorphone in the absence of the other constituents in 
the formulation, which affected our ability to determine if the drug alone impacts HIV 
viability and retention on the IDPE. However, we believe that it is more likely that 
excipients in the long-acting drug preparations may contribute to HIV persistence. 
Cellulose-containing drugs may maintain hydration, resulting in virus preservation. In fact, 
methyl cellulose derivatives are a major constituent in media to maintain hydration and 
limit diffusion for viral plaque assays used for clinical diagnostics [24]. 
5.6.4 Harm Reduction Implications 
While HIV transmission from sharing needles/syringes has been well established,9 
transmission associated with sharing IDPE in the absence of needle/syringe sharing has 
only been suggested [25,26]. As a result, harm reduction education for persons who inject 
drugs often emphasizes the risk of sharing needles/syringes, but not IDPE.7 Future harm 
reduction education should emphasize the importance of not sharing IDPE, as this behavior 
could reduce the incidence of HIV among persons who inject drugs. However, it is unlikely 
that a campaign focusing on the prevention of IDPE sharing alone would be successful, 
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given the economic pressures to maximize utilization of the very expensive residual 
hydromorphone. 
We found that HIV+ cases were more likely to believe that heating hydromorphone during 
preparation was not necessary or was harmful to drug availability (believing it “boiled off 
the dope”). A previous study showed that HIV is inactivated with heating IDPE, although 
this was not studied in the presence of prescribed opioids [27]. We demonstrated that 
heating IDPE until boiling is an effective means of inactivating HIV, even in the presence 
of a controlled-release opioid. Heating maintained the same dose of active hydromorphone 
in the injectate, and therefore would not contribute to increased rates of overdosing or 
discourage drug users who are afraid of reducing drug availability. Thus, HIV transmission 
may be attenuated by promoting the message to “cook the wash” (i.e. heat the wash with a 
lighter until bubbling) if reusing IDPE.  
Based upon the results of the above investigations a community education project was 
carried out starting on June 15, 2017. This involved peer mentors, injection equipment 
distribution staff, HIV healthcare navigators, and public health officials spreading a 
message to PWIDs to “cook your wash” i.e., heat the IDPE containing the drug and filter 
and water with a cigarette lighter until bubbling prior to any injection of hydromorphone. 
Local mass media was also used to spread this message. Results of this campaign will be 
presented at a later date. 
Using a sterile needle for every aspirate of a drug is also useful in preventing viral 
contamination of the IDPE, but this alone will not reduce the risk of bacterial contamination 
of the injectate from repeated handling; boiling is necessary to reduce this potential 
bacterial load (data not shown). Cleaning the IDPE with bleach prior to reuse has been 
occasionally recommended, although it would not be acceptable in the context of retained 
drug and injectate being exposed to the caustic effects of bleach. Recognizing that the 
formulation of hydromorphone controlled-release is a specific risk factor for reuse, the 
provision of injectable hydromorphone should also be considered, as per the SALOME 
trials [28]. 
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5.6.5 HIV Transmission in Other Regions 
We suspect that HIV transmission in association with sharing IDPE may be occurring in 
other regions as well. There have been several recent large injection drug use-associated 
HIV outbreaks including an ongoing outbreak in Saskatchewan, where hydromorphone 
controlled-release is the opioid of choice [30]. Similarly, the opioid of choice in a recent 
outbreak in Indiana was a controlled-release preparation containing microcrystalline 
cellulose [oxymorphone hydrochloride extended-release (Opana ER®, Endo International 
PLC, Malvern Pennsylvania)]; [31] a drug that has also been associated with IDPE sharing 
and HCV transmission [2,10,31]. The risk of HIV and HCV infection associated with illicit 
use of oxymorphone extended-release resulted in its removal from the US market [29], 
although it is still available in Canada and Europe.   
5.6.6 Study Limitations 
The major exposure of interest was sharing of IDPE. As this was identified retrospectively 
in a case control design, the possibility of recall bias cannot be ruled out. However, it is 
notable that HIV infected patients were no more likely to recall sharing of needles/syringes 
than HIV uninfected patients and so we do not believe that recall bias was leading case 
patients to non-specifically report more risky behaviors.   
As the focus of this study was on HIV transmission associated with Injection Drug Use, 
some sexual risk factors for HIV were not fully investigated (e.g. unprotected sex, multiple 
partners). Report of beliefs and attitudes regarding heating IDPE prior to injection was not 
available for several participants, and so this could not be placed into the multiple 
regression analysis and only an unadjusted analysis of these data could be presented.  
Hydromorphone immediate-release use was associated with a protective effect in 
unadjusted analysis, as it tends to be used by local persons who inject drugs in substitution 
for Hydromorphone controlled-release when the latter is unavailable or unaffordable. 
Therefore, increased hydromorphone immediate-release use would suggest decreased 
controlled-release availability, and we believe that the controlled release formulation was 
most important in transmission.  
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5.7 Conclusion 
The recent outbreaks of HIV in PWID emphasize the need for understanding all 
mechanisms of transmission and the development of new tools in the fight against HIV 
transmission in this population. This community suffered an outbreak of HIV despite 
having excellent pre-existing traditional programs for harm reduction and HIV prevention. 
Our data demonstrated that the widespread local abuse of a controlled release opioid which 
encouraged reuse and sharing of IDPE when injecting, and the increased HIV survival in 
the IDPE, contributed to the significant infectiousness of the practice. Preventing IDPE 
sharing will be difficult due to the retention of valued drug in the IDPE after use. Heating 
IDPE prior to each use may provide an effective harm reduction approach to reducing HIV 
infection. As the popularity of injecting prescription opioids continues to increase [5,30], 
implementation of harm reduction strategies that target sharing IDPE as a mechanism of 
transmission will become increasingly important. 
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Supplementary Figure 5.1) Preservation of infectious HIV in Injection Drug 
Preparation Equipment with different Filters and Opiate Preparations 
A) HIV-1 was spiked into IDPEs 
with varying opioids and syringe 
filters to measure viral 
persistence. HIV-1 isolated from 
the syringe filters after 72 hours 
was quantified via Reverse 
Transcriptase assay.  * 
significant at p<0.05, ** 
significant at p<0.01 via two-
way ANOVA with Tukey’s 
correction for multiple 
comparisons. B) HIV-1 isolated 
from the injectates pulled 
through each filter type after 72 
hours was quantified via Reverse 
Transcriptase assay.  
Apothicom® filters are made of 
tightly woven cotton coated in 
methylethyl-cellulose while 
dental filters are loosely woven, 
undyed cotton. Virus Reverse 
Transcriptase activity was best 
preserved using 
Hydromorphone controlled-
release and Apothicom® filters. 
Dashed line represents assay 
detection limit. Error bars 
represent standard error. * 
significant at p<0.05, ** at 
p<0.001 via via two-way 
ANOVA with Tukey’s 
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